Screening assays for agonists and antagonists of receptor activator of NF-κB

ABSTRACT

The present invention provides methods for screening for a molecule that antagonizes or agonizes RANK activity. One aspect of the invention involves the growth of RANK responsive cells in semi-solid medium, wherein exposure to a RANK antagonist promotes colony formation. Other aspects of the invention rely on promoter/reporter constructs using RANK responsive promoters derived from the MMP-9 and TRAP genes. Additional aspects of the invention exploit the ability of RANK to activate c-src activity, F-actin ring formation and CaPO 4  resorption.

This application claims the benefit of priority from U.S. provisionalpatent application No. 60/235,157, filed Sep. 22, 2000, which is herebyincorporated by reference in its entirety.

FIELD OF THE INVENTION

This invention relates to methods for screening for agonists and/orantagonists of activities associated with receptor activator of NF-κB(RANK).

BACKGROUND OF THE INVENTION

RANK, an acronym for receptor activator of NF-κB, is a Type Itransmembrane protein that is a member of the tumor necrosis factor(TNF) receptor superfamily and which when triggered activates thetranscription factor NF-κB (Anderson et al., Nature 390:175-179 (1997);Anderson et al., U.S. Pat. No. 6,017,729). The human RANK (616 aminoacids) has a signal peptide (28 amino acids), an N-terminalextracellular domain (184 amino acids), a short transmembrane domain (21amino acids), and a large C-terminal cytoplasmic domain (383 aminoacids), and mouse RANK is similarly arranged (Anderson et al., 1997).The extracellular domain of RANK contains four cysteine-richpseudorepeats and two N-glycosylation sites, which features arecharacteristic of members of the TNF receptor superfamily. RANK has a40% homology with CD40 (Anderson et al., 1997), and is expressed on Tcells, dendritic cells, and osteoclasts (Anderson et al., 1997; Hofbaueret al., J Bone Min Res 15:2-12 (2000)).

The cytoplasmic domain of RANK associates intracellularly with severalof the TNF receptor-associated factors (TRAFs; Baker and Reddy, Oncogene12:1 (1996)) including TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6 (Galibertet al., J Biol Chem 273:34120-27 (1998)). These TRAF binding sites areclustered in two distinct domains in the RANK cytoplasmic tail. TheTRAFs are cytoplasmic proteins that often mediate signal transduction bymembers of the TNF receptor superfamily, and they are important in theregulation of, for example, immune and inflammatory responses. RANKmediates some or all of its biological activities through a cascade ofevents that involves the TRAF binding sites (see, for example, Galibertet al., 1998).

Triggering of RANK, such as by contact with membrane-bound or solubleRANK-L, results in the stimulation of RANK-mediated cellular responses.These cellular responses can include the activation of transcriptionfactor NF-κB, a ubiquitous transcription factor that is extensivelyutilized in cells of the immune system, or the activation of Jun kinase(JNK; see, for example, Galibert et al., 1998). RANK activation inosteoclast progenitor cells induces the progenitors to differentiateinto mature osteoclasts. This differentiation process is accompanied bythe rearrangement of actin into “F-actin rings,” a specialized structurethat is detectable by staining (Lakkakorpi, P. and Vaananen, J. Bone MinRes 6:817-826 (1991)). Elevated levels of c-src tyrosine kinase activityis also associated with RANK activation (Wong et al. Molecular Cell4:1041-1049 (1999)).

RANK ligand (RANK-L) is a cell surface protein that binds with andactivates RANK (Anderson et al., U.S. Pat. No. 6,017,729). This proteinis also known as TRANCE, ODF or OPG ligand (Wong et al., 1999). RANK-Lis a Type 2 transmembrane protein, and has an intracellular domain ofabout 50 amino acids or less, a transmembrane domain and anextracellular domain of about 240 to 250 amino acids. The extracellulardomain of RANK-L contains a RANK-binding site. Similar to other membersof the TNF family to which it belongs, RANK-L has a “spacer” regionbetween the transmembrane domain and the receptor binding domain that isnot necessary for receptor binding.

In bone, RANK-L stimulates osteoclast differentiation, enhances theactivity of mature osteoclasts, and inhibits osteoclast apoptosis,thereby expanding the pool of activated osteoclasts (see, for example,Hsu et al., Proc Nat'l Acad Sci USA. 96:3540-45 (1999)). Osteoclasts arelarge, phagocytic, multinucleated cells which are formed fromhematopoietic precursor cells in the bone marrow. Osteoclasts promotedissolution of the bone matrix and solubilization of bone salts, and arerequired for the proper development and growth of bones.

RANK knock-out mice are severely osteopetrotic and lack peripheral lymphnodes (Dougall et al., Genes Dev. 13:2412-24 (1999)). Modulation of RANKand RANK-L activity has been proposed as a means for treating a varietyof disorders that involve osteopenia or osteopetrosis, including, forexample, osteoporosis, Paget's disease, hypercalcemia, and so on (see,for example, WO 98/46751 and WO 99/58674).

RANK and its ligand play an integral role in the regulation of a widerange of biological systems, including the immune response, theinflammatory response, and bone remodeling through activation ofosteoclasts. In view of the importance of RANK in the regulation of awide range of biological systems, there is a need for methods forscreening for molecules that antagonize or agonize RANK activity.

SUMMARY OF THE INVENTION

The present invention provides methods for screening for a molecule thatantagonizes or agonizes RANK activity.

In one embodiment of the invention, assays for RANK agonists orantagonists involve culturing RANK responsive cells in a semi-solidmedium in the presence of a candidate molecule and determining whethercompared with a control culture the rate of colony formation or rate ofcolony growth is enhanced or reduced in cells that have been contactedwith the candidate molecule. In this assay, a candidate molecule isidentified as being a RANK antagonist if the rate of colony formation orcolony growth in the contacted cells, also called “test cells,” isenhanced as compared with the rate of colony formation or growth in thecontrol reference cells that are not contacted with the candidatemolecule, or as a RANK agonist if the rate is comparatively reduced.Except for contact with the candidate molecule, control reference cellsare otherwise cultured and handled in the same manner as the testcultures.

In one aspect of the invention, the semi-solid medium used ismethylcellulose, though soft agar, soft agarose or the like also may beused.

If desired, candidate molecules can be batched for this assay. In thisapproach, a plurality of candidate molecules are added to a testculture. If RANK activity modulation is observed in such cultures, eachcandidate molecule in the batch can then be tested separately andantagonists or agonists identified individually.

When the semi-solid medium assay is used to screen for molecules thatantagonize RANK activity, RANK is triggered in the RANK responsive cellsbefore, during and/or after the exposure of the test cells to thecandidate molecule. As used herein, RANK triggering refers to some eventthat stimulates the RANK protein to transduce a signal to the cell inwhich it is being expressed. Cells useful in this first aspect of theinvention express RANK protein, are capable of forming colonies in asemi-solid medium, and are stimulated by the action of one or moreRANK-mediated cellular signaling pathways to differentiate into celltypes that cannot form colonies in semi-solid medium.

When RANK activity is stimulated in RANK responsive cells for thesemi-solid medium assays of the invention, preferred methods ofstimulation include: contacting the RANK responsive cells with a RANK-Lpolypeptide, such as a RANK-L polypeptide comprising amino acids 162-317of SEQ ID NO:6 or amino acids 161-316 of SEQ ID NO:8; contacting theRANK responsive cells with agonistic anti-RANK antibodies; contactingthe RANK responsive cells with one or more cells that express a RANK-Lpolypeptide; overexpressing RANK in the RANK responsive cells; andexpressing in the RANK responsive cells a mutant form of RANK thatinduces RANK signaling at normal levels of RANK expression in theabsence of RANK-L. An example of the latter type of RANK is FEO RANK(SEQ ID NOS:9 and 10).

Exemplary RANK-L polypeptides for stimulating RANK activity includenative RANK-L, such as endogenous RANK-L that is expressed on thesurfaces of cells, soluble forms of RANK-L, a leucine zipper fusion ofRANK-L, and a FLAG™ polyHis fusion of RANK-L. Another method forstimulating RANK activity for the subject assays is to contact the RANKresponsive cells with an agonistic anti-RANK antibody. Exemplaryagonistic anti-RANK antibodies for this purpose include M330 antibodiesand M331 antibodies, both of which are directed against human RANK, andM395 and M396 antibodies, which are directed against murine RANK.

In one aspect of the invention, the rate of colony formation or colonygrowth in semi-solid medium is determined by visual inspection of theplates after the cells have been exposed to the candidate molecules. Thenumbers of colonies or sizes of observed colonies is compared for platesexposed to the candidate molecule and similar cultures not exposed tothe candidate molecules.

One means of contacting the RANK responsive cells with a candidatemolecule involves introducing into the test cells a DNA molecule thatencodes either a candidate nucleic acid molecule or that encodes acandidate protein molecule. For example, the introduced DNA can be acDNA molecule encoding a single protein or a cDNA library encoding agroup of proteins to be tested. After being introduced into the cell,this DNA may or may not become integrated into the genome of the RANKresponsive cells. Techniques for stable transfection and transienttransfection are known, and either type of technique may be used. Insome instances, the encoded candidate molecule is a nucleic acidmolecule, such as an anti-sense oligonucleotide or an RNA with ribozymeactivity. In one aspect of the invention, cDNAs determined to encode aRANK agonist or antagonist are isolated and purified from colonies oftest cells that are growing in semi-solid medium.

Other means of contacting the RANK responsive cells with candidatemolecules involve adding the candidate molecule directly to thesemi-solid medium, either by mixing it with the medium before pouringthe plates, or by overlaying the poured plates with a layer of mediumcontaining the candidate molecule. For example, the foregoing methodsmay be used when the candidate molecule is a protein or small organicmolecule. If desired, a plurality of proteins or other test moleculesmay be added to the test cultures.

In one aspect of the invention, RANK responsive cells are employed thatexpress a defective RANK molecule and the screening is for an agonistthat complements this defective RANK molecule. An exemplary defectiveRANK for this purpose is human RANKΔ340-42.

Suitable RANK responsive cells for the above described assays includeprimary hematopoietic cells, including hematopoietic precursor cellsderived from bone marrow, spleen, fetal liver or peripheral blood, aswell as primary hematopoietic cells derived from bone marrow, spleen,fetal liver or peripheral blood and enriched for osteoclast precursors.In other aspects of the invention, the RANK responsive cells are a cellline. Suitable cell lines include RAW 264.7 cells, C7 cells, andBCL-X1/Tag cells.

Another aspect of the invention exploits the ability of promotersequences derived from the tartrate-resistant acid phosphatase (TRAP)gene (SEQ ID NO:12) or the MMP-9 gene (SEQ ID NO:11) to respond directlyto signal transduction resulting from RANK triggering. In a preferredembodiment, the MMP-9 promoter comprises nucleotides 1769-3591 of SEQ IDNO:11. The present invention provides methods for screening for a RANKagonist or antagonist by employing recombinant DNA constructs in which aTRAP or MMP-9 promoter is operably linked to a nucleic acid moleculethat encodes a reporter protein. Reporter proteins suitable for thispurpose include, for example, luciferase, β-galactosidase, greenfluorescent protein, alkaline phosphatase or a heterologous surfaceprotein detectable by antibody binding methods. Examples of the latterinclude human IL-2 receptor, murine IL-4 receptor, human CD2 protein,human CD4 protein and human CD8 protein.

For these assays, a reporter/promoter construct as described herein isintroduced into cultured RANK responsive cells. Suitable RANK responsivecells include hematopoietic cells. Examples of suitable hematopoieticcells include RAW 264.7 cells. To use this approach to screen for a RANKantagonist, the constructs are introduced into the test cells, whichthen are treated with a RANK activity agonist, such as soluble RANK-L,which triggers RANK in the cells, thereby activating the promoteractivity in the construct, resulting in expression of the reporter gene.Candidate antagonist molecules are contacted with the triggered cells totest for their ability to suppress this RANK-mediated reporter geneexpression. The test cells are contacted with the candidate antagonistbefore, during or after the RANK triggering step.

Candidate molecules, for example, may be added to the culture medium. Inone embodiment of the invention, the candidate molecule is a protein; inanother embodiment it is a small organic molecule.

In one aspect of the invention, the candidate molecule is a protein orgroup of proteins encoded by cDNA that is introduced into the test cellsprior to cells' being exposed to the RANK trigger. Generally, the cDNAis introduced at least 48 hours prior to triggering RANK. The cDNA canbe isolated from cells that exhibit an altered level of reporter geneexpression.

Suitable methods for triggering RANK in the above-describedreporter/promoter construct assays include exposing the test cells tocells that express RANK-L on their surfaces, exposing the test cells tosoluble RANK-L, overexpressing RANK in the test cells, expressing humanRANKΔ340-42 in the test cells, or exposing the test cells to anagonistic antibody specific for the RANK protein. In one aspect of theinvention, RANK is triggered in the RANK responsive cells by contactingthem with a RANK-L polypeptide that includes amino acids 162-317 of SEQID NO:6 or amino acids 161-316 of SEQ ID NO:8.

Test cells in which RANK has been triggered are contacted with thecandidate molecule and the cells then are analyzed to determine whetherthe level of reporter protein expression is enhanced or reduced as aresult of this contact. The level of reporter expression is determinedby any suitable assay, such as a fluorescence-based assay, acolorimetric assay, a solid phase assay, or assays employing aradioactive compound. One means of determining levels of reporter geneproduct is to use conventional methods to physically isolate byfluorescence-based cell sorting those cells that are expressing thereporter molecule. Enhancement or reduction of reporter proteinexpression in the test cells is determined by comparing the level ofreporter protein expression in the test cells with the level ofexpression in control cultures that are not contacted with the candidatemolecule. If the candidate molecule is a RANK antagonist, the level ofreporter expression will be comparatively reduced.

The above-described constructs also are used to screen for RANKagonists. In this instance, RANK is not deliberately triggered in thetest cells, but rather the candidate molecule is assessed for itsability to trigger RANK. Cells useful in this aspect of the inventionexpress RANK protein and contain at least one signal transductionpathway that is stimulated by the activation of RANK. In some instances,the agonist is contacted with the cells by introducing into the cells acDNA encoding a candidate protein agonist, or by introducing a cDNAlibrary encoding a plurality of candidate protein agonists. In suchinstances, an agonist can be isolated by recovering and purifying thecDNA from those colonies that exhibit enhanced reporter gene expression.Furthermore, it can be demonstrated using conventional techniques thatthe purified candidate molecule indeed interacts with RANK.

In one aspect of the invention, the reporter/promoter constructs areused to identify RANK agonists by using cells that express a defectiveRANK molecule and the screening is for an agonist that complements thedefective RANK activity. For example, cells expressing human RANKΔ340-42may be used for this purpose.

In another aspect of the invention, screening for antagonists oragonists of RANK activity involves contacting a candidate molecule withRANK responsive cells that are capable of differentiating intoosteoclasts in response to the triggering of RANK. To screen for RANKantagonists, one triggers RANK in the cells, exposes the cells to thecandidate antagonist, and observes the level of c-src activity orF-actin formation as compared to the level of c-src activity or F-actinformation in reference RANK responsive cells that are not contacted withthe candidate molecule. If the candidate is an antagonist, the rate ofc-src activity and F-actin ring formation will be comparatively reduced.If the candidate is to be screened for RANK agonist activity, the RANKtriggering step is omitted and a positive result will consist ofobserving enhanced c-src activation and F-actin formation.

In yet another aspect of the invention, candidate RANK agonists orantagonists are screened by contacting a candidate molecule with RANKresponsive cells that are capable of differentiating into osteoclasts inresponse to the triggering of RANK in said cells, triggering RANK in thecells, then culturing the cells on a film of CaPO₄. Differentiatedosteoclasts will resorb the CaPO₄ in their immediate vicinity, thusproducing a pit in the film. One then compares the number of pits in thefilm that are caused by the contacted cultured cells versus the numberof pits caused in a similar film by reference RANK responsive cells inwhich RANK is triggered but which are not contacted with the candidatemolecule. One then can identify a candidate molecule as a RANK agonistif a greater number of pits is caused by the candidate molecule-treatedcells than by the reference cells and as a RANK antagonist if the numberof pits caused by the treated cells is less than the number caused bythe control cells.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention provides methods for screening for a molecule thatantagonizes or agonizes RANK activity. Although various assays fordetecting antagonists and agonists of RANK are known in the art (see,for example, U.S. Pat. No. 6,017,729), the screening strategiesdescribed herein have not been previously described.

As used herein, the term “RANK agonist,” or grammatical equivalentsthereof, refers to a molecule that stimulates RANK activity, including amolecule that triggers RANK. A RANK agonist can interact directly withRANK, or may enhance RANK activity indirectly. RANK-L, for example,would be considered to be a RANK agonist. Also, antibodies thatspecifically bind RANK often act as agonists of RANK activity.

As used herein, the term “RANK antagonist,” or grammatical equivalentsthereof, refers to a molecule that inhibits RANK activity. A RANKantagonist can interact directly or indirectly with RANK. RANK:Fc(described in U.S. Pat. No. 6,017,729) and osteoprotegerin (described inU.S. Pat. No. 6,015,938) are examples of RANK antagonists, the formerbeing a fusion protein containing the extracellular domain of RANK fusedwith the Fc region of immunoglobulin, and the latter being anaturally-occurring protein. These two proteins antagonize RANK bybinding RANK-L, thereby preventing the RANK-L from binding with RANKresponsive cells.

The term “RANK” as used herein refers to a protein having the ability toactivate NF-κB or the ability to bind with TRAF1, TRAF2, TRAF3, TRAF5 orTRAF6, and having an at least 80% amino acid identity with the aminoacid sequence shown in SEQ ID NO:2 or SEQ ID NO:4. RANK proteinsaccording to the invention are capable of binding with antibodies thatbind specifically to a protein having the amino acid sequence of SEQ IDNO:2 or SEQ ID NO:4.

The term “RANK-L” is an acronym for RANK ligand, which is a Type 2transmembrane protein that binds to and activates RANK. The sequences oftwo nucleic acid molecules encoding representative RANK-L proteins areset forth in SEQ ID NO:5 (human RANK-L) and SEQ ID NO:7 (murine RANK-L),and the sequences of the RANK-L proteins encoded by these two nucleicacid sequences are set forth in SEQ ID NO:6 and SEQ ID NO:8,respectively. It is understood that “RANK-L” as used herein includesboth full-length RANK-L proteins as well as membrane-bound or solubleforms of the RANK-L protein, including chimeric molecules comprisingportions of RANK-L and multimeric RANK-L molecules.

RANK and RANK-L are involved in controlling formation of matureosteoclasts, the primary cell type implicated in bone resorption. Anincrease in the rate of bone resorption (over that of bone formation)can lead to various bone disorders which are collectively referred to asosteopenias, and include osteoporosis, osteomyelitis, hypercalcemia,osteopenia brought on by surgery or steroid administration, Paget'sdisease, osteonecrosis, bone loss due to rheumatoid arthritis,periodontal bone loss, prosthetic loss or loosening and osteolyticmetastasis. Agonists and antagonists of RANK can be used to modulateosteoclast formation and may be administered to patients suffering frombone disorders to ameliorate these conditions.

Further, many cancers metastasize to bone and induce bone breakdown bylocally disrupting normal bone remodeling. Such cancers can beassociated with enhanced numbers of osteoclasts and enhanced amount ofosteoclastic bone resorption resulting in hypercalcemia (see, forexample, Guise et al. Endocrine Reviews, 19(1):18-54, 1998.). Othercancers do not necessarily metastasize to bone, but result inhypercalcemia and bone loss (e.g., squamous cell carcinomas). Agonistsand antagonists of RANK may be administered to patients suffering fromcancer to ameliorate the symptoms thereof, including but are not limitedto those suffering from breast cancer, multiple myeloma, melanoma, lungcancer, prostate, hematologic, head and neck, and renal cancer.Antagonists of the RANK/RANKL interaction are particularly useful fortreating cancer.

In addition, RANK antagonists or agonists identified by the presentscreening assays can be used to prevent or treat cardiovascular diseasesand other conditions characterized by arterial calcification. Also, theantagonists and agonists of RANK identified herein are useful intreating immune diseases and/or inflammatory diseases, such as toxic orseptic shock, or graft-versus-host reactions (such as via the inhibitionof NF-PB activation). As RANK triggering stimulates T cell activation,the RANK agonists identified herein are useful as vaccine adjuvants.

Tumor cells are more responsive to radiation when their NF-κB isblocked; thus, antagonists of RANK signaling will be useful as anadjunct therapy for disease characterized by neoplastic cells thatexpress RANK. Conversely, agonists of RANK will be useful forstimulating RANK-mediated cellular responses, and certain RANK agonistsmay be capable of complementing inactive RANK mutants.

Candidate Molecules to be Tested for RANK Agonist or AntagonistActivity:

Examples of candidate molecules, also referred to herein as “testmolecules,” to be tested for RANK agonist or antagonist activityinclude, but are not limited to, carbohydrates, small molecules (usuallyorganic molecules or peptides), proteins, and nucleic acid molecules(including oligonucleotide fragments typically consisting of from 8 to30 nucleic acid residues). Peptides to be tested typically consist offrom 5 to 25 amino acid residues. Also, candidate nucleic acid moleculescan be antisense nucleic acid sequences, and/or can possess ribozymeactivity. If desired, antisense or ribozyrne RNAs can be introduced intoa target cell by means of introducing into the cells a DNA molecule thatencodes the antisense or ribozyme RNA.

Small molecules to be screened using the hereindescribed screeningassays can typically be administered orally or by injection to a patientin need thereof. Small molecules that can be administered orally areespecially preferred. The small molecules of the invention preferablywill not be toxic at the doses required for them to be effective aspharmaceutical agents, and they are preferably not subject to rapid lossof activity in the body, such as the loss of activity that might resultfrom rapid enzymatic or chemical degradation. In addition,pharmaceutically useful small molecules are preferably not immunogenic.

The methods of the invention can be used to screen for antisensemolecules that inhibit RANK activity by virtue of interfering with thefunctional expression of one or more mRNA molecules that encode one ormore proteins that mediate a RANK-dependent cellular response. Ananti-sense nucleic acid molecules are complementary to a nucleic acidtarget expressed within the host cell and by forming duplexes with thetarget thus hinder the target from functioning. Anti-sense nucleic acidsmay block the transcription of a target gene by duplexing with eitherstrand of the DNA encoding the gene, or by duplexing with a regulatoryelement that controls expression of the target gene. Alternatively, itmay duplex with an mRNA, thus hindering or blocking its translation. Ananti-sense nucleic acid molecule may be constructed in a number ofdifferent ways provided that it is capable of interfering with theexpression of a target gene. Typical anti-sense oligonucleotides to bescreened preferably are 20-50 nucleotides in length, and more preferablyare 30-40 nucleotides in length. The anti-sense nucleic acid moleculegenerally will be substantially identical in nucleotide sequence to onestrand of the target gene. The minimal identity will typically begreater than about 65%, but a higher identity might exert a moreeffective repression of expression of the endogenous sequences.Substantially greater identity of more than about 80% is preferred,though about 95% to absolute identity is most preferred.

Candidate nucleic acid molecules can possess ribozyme activity. Thus,the methods of the invention can be used to screen for ribozymemolecules that inhibit the functional expression of one or more mRNAmolecules that encode one or more proteins that mediate a RANK dependentcellular response. Ribozymes are catalytic RNA molecules that can cleavenucleic acid molecules having a sequence that is completely or partiallyhomologous to the sequence of the ribozyme. It is possible to designribozyme transgenes that encode RNA ribozyrnes that specifically pairwith a target RNA and cleave the phosphodiester backbone at a specificlocation, thereby functionally inactivating the target RNA. In carryingout this cleavage, the ribozyme is not itself altered, and thus iscapable of continuing to cleave other target RNA molecules. Theinclusion of ribozyme sequences within antisense RNAs confersRNA-cleaving activity upon them, thereby increasing the activity of theantisense constructs.

The design and use of target RNA-specific ribozymes is described inHaseloffet al. (Nature, 334: 585-591(1988))(see also U.S. Pat. No.5,646,023), both of which publications are incorporated herein byreference. Tabler et al. (Gene 108:175 (1991)) have greatly simplifiedthe construction of catalytic RNAs by combining the advantages of theanti-sense RNA and the ribozyme technologies in a single construct.Smaller regions of homology are required for ribozyme catalysis,therefore this can promote the repression of different members of alarge gene family if the cleavage sites are conserved.

RANK and RANK-L Molecules

Generally, the screening assays described herein involve a RANK or aRANK-L protein.

RANK and its binding partner RANK-L and nucleic acids encoding theseproteins are known in the art and have been well-characterized withrespect to their physical properties, their disposition within the cell,and with respect to may of the biological activities associated with thebinding of RANK and RANK-L. Examples of murine and/or human RANK as wellas examples of murine and/or human RANK-L are disclosed in U.S. Pat. No.6,017,729, U.S. Pat. No. 5,843,678 (disclosing “osteoprotegerin bindingprotein,” which is described herein as murine RANK-L), WO 98/25958(disclosing “488E9, ” which is described herein as murine RANK-L); WO98/44751 (disclosing murine “ODAR,” referred to herein as murine RANK);and EP 0 911 342 (disclosing “OCIF-binding molecule,” referred to hereinas murine RANK-L). Others have disclosed RANK-L, referring to it as“TRANCE” (see, for example, Wong et al., Molec Cell 4:1041-49 (1999)).Any of these RANK and RANK-L molecules may be used in the assaysdescribed herein.

The sequences of two nucleic acid molecules encoding representative RANKproteins are set forth in SEQ ID NO:1 (human RANK) and SEQ ID NO:3(murine RANK), and amino acid sequences encoded by these nucleic acidmolecules are set forth in SEQ ID NOS:2 and 4, respectively. Thesequences of exemplary human and mouse RANK-L sequences are shown in SEQID NOS:6 and 8, and nucleic acids encoding these proteins in SEQ IDNOS:5 and 7. However, it is understood that other RANK and RANK-Lvariants other than those shown in these examples may be used in thehereindisclosed assays, including other RANK and RANK-L molecules knownin the art, or variants having amino acid differences that do notinfluence the binding of RANK to RANK-L nor the triggering of RANK thatnormally results from this binding.

Sequence variants of native RANK and RANK-L polypeptides are useful inthe practice of the present invention in any instance where the nativeRANK or RANK-L polypeptide is utilized, provided that the variantpossesses any biological activity required for the assay. Generally forthese assays, suitable RANK variants will bind RANK-L therebystimulating RANK activity, and suitable RANK-L variants will bind toRANK thereby stimulating RANK activity. Mutations present in suchvariants may include, for example, substitutions, deletions, andinsertions of amino acids. Allelic forms or mutated forms of RANK andRANK-L can be obtained for use in these assays by using a variety oftechniques known in the art, including, for example, site-directedmutagenesis, oligonucleotide-directed mutagenesis, and so on.

RANK molecules useful for the disclosed methods include wild-type RANKas well as variant forms of RANK. The variants may differ in amino acidsequence from the RANK molecules of SEQ ID NOS:2 or 4, but will retainthe ability to transduce at least one of the biological signals that isassociated with the triggering of wild-type RANK, such as activation ofNF-κB. Suitable variants include naturally-occurring allelic variants,mutant forms of RANK (such as FEO RANK) or variants constructed usingrecombinant DNA technology.

RANK-L proteins, including soluble forms of RANK-L, useful fortriggering RANK will contain the RANK binding domain, which is containedin the extracellular region of the molecule. For human RANK-L, theextracellular domain encompasses about 249 amino acids at the carboxyend of the protein (amino acids 69 through 317 of SEQ ID NO:6), and formouse RANK-L encompasses about 247 amino acids at the carboxy terminusof the protein (amino acids 70-316 of SEQ ID NO:8). Soluble RANK-L fortriggering RANK may comprise the entire extracellular region, or maycomprise only that portion of RANK-L that contains the RANK-bindingdomain, which for human RANK-L is found in a fragment having amino acids69 to 317 of SEQ ID NO:6, or more preferably having amino acids 162-317of SEQ ID NO:6, or for murine RANK-L in a fragment having amino acids 70to 316 of SEQ ID NO:8, or more preferably having amino acids 161-316 ofSEQ ID NO:8.

Soluble RANK-L for triggering RANK may further comprise a signal peptidethat directs secretion of the soluble protein, and also may furthercomprise a second polypeptide, such as, for example, a polypeptide whichwhen present will stimulate oligomerization of the soluble RANK-L fusionprotein. RANK-L fragments for constructing soluble RANK-Ls can beprepared using known recombinant techniques to isolate a desired portionof the extracellular region. Various RANK-L derivatives for triggeringRANK include covalent or aggregative conjugates of the proteins or theirfragments with other proteins or polypeptides, such as by synthesis inrecombinant culture as N-terminal or C-terminal fusions. For example,the conjugated peptide may be a signal (or leader) polypeptide sequenceat the N-terminal region of the protein which co-translationally orpost-translationally directs transfer of the protein from its site ofsynthesis to its site of function outside of the cell membrane or wall(e.g., the yeast α-factor leader). Alternatively, RANK-L may beconjugated in some instances with a poly-His or FLAG® tag as describedin U.S. Pat. No. 6,017,729.

Generally, if RANK-L is being used to trigger RANK, the RANK-L isderived from the same species (for example, human) from which the RANKis derived. However, mouse RANK-L is capable of triggering human RANK,and human RANK-L is capable of triggering mouse RANK.

RANK proteins useful in the practice of the present invention typicallyhave an amino acid sequence that is at least 80% identical, or at least85% identical, or preferably at least 90% identical to all or a portionof the native RANK amino acid sequences set forth in SEQ ID NOS:2 or 4.RANK-L proteins useful in the practice of the present inventiontypically have an amino acid sequence that is at least 80% identical, orat least 85% identical, or preferably at least 90% identical to all or aportion of the native RANK-L amino acid sequences set forth in SEQ IDNOS:6 or 8. The RANK proteins of the invention when triggered arecapable of activating NF-κB activity.

Percent identity is determined as follows. Amino acid sequence identityis defined as the percentage of the amino acid residues set forth in SEQID NOS:2, 4, 6 or 8 that are identical with part or all of anotherprotein sequence (which may be a portion of a larger protein sequence)after aligning the sequences and introducing gaps, if necessary, toachieve the maximum percent identity. For comparing amino acid sequencesof unequal length, the percent identity is calculated based on thesmaller of the two sequences. Percent identity may be determined using acomputer program, for example, the GAP computer program described byDevereux et al. (Nucl. Acids Res 12:387, 1984), which is available fromthe University of Wisconsin Genetics Computer Group (UWGCG), or anyother suitable computer program that is capable of aligning andcomparing two or more amino acid sequences. When using the GAP program,preferred default parameters for conducting the comparison include: (1)a unary comparison matrix (containing a value of 1 for identities and 0for non-identities) for amino acids, and the weighted comparison matrixof Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as described bySchwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure,National Biomedical Research Foundation, pp. 353-358, 1979; (2) apenalty of 3.0 for each gap and an additional 0.10 penalty for eachsymbol in each gap; and (3) no penalty for end gaps. Another programuseful for determining percent identify is the BESTFIT program, alsoavailable from the University of Wisconsin as part of the GCG computerpackage. Default parameters for using the BESTFIT program are the sameas those described above for using the GAP program.

Some embodiments of the invention employ mutant forms of the RANKprotein. An example of this type of RANK mutant is the mutated form ofRANK isolated from patients having a condition known as “familialexpansile osteolysis” (FEO), which is a rare autosomal dominant bonedysplasia with similarities to Paget's disease of bone. These diseasesare characterized by focal areas of increased bone remodeling that leadsto deformity and disability. The FEO gene and the gene associated withfamilial Paget's disease of the bone map to chromosome 18q21 which isthe same location that includes the RANK gene. An exemplary FEO RANK DNAis described in Hughes et al., Nat Genet 24:45-48 (2000).

Mutant forms of RANK are especially useful in assays designed toidentify molecules capable of complementing the defect in cellsexpressing this form of RANK, as such molecules can serve as therapeuticagents to treat diseases associated with the RANK mutation. The assaysdescribed herein are useful for screening for molecules that possess thecapacity to complement the RANK defect in the FEO RANK gene. Thesequences for an FEO RANK are given in SEQ ID NOS:9 and 10. Moleculeswith this capacity are “FEO RANK agonists” and will be useful fortreating patients suffering from FEO, Paget's disease or relateddiseases, or for developing agents to be used for this purpose. It isanticipated that RANK mutations will be found to play a role in bonediseases other than FEO and Paget's. DNA encoding these mutated forms ofRANK will be isolated and tested in the hereindescribed screening assaysto identify treatments for the diseases.

RANK Activation:

Many of the assays described herein involve the use of RANK responsivecells. As used herein, the phrase “RANK responsive cell” refers to acell that expresses a membrane-bound RANK protein that is capable oftransducing an intracellular signal or stimulating a discemablebiological response in the cell (such as differentiation from one celltype into another cell type) when the RANK protein is triggered bybinding to a RANK-L or when the RANK is triggered by some other means.

As used herein, the phrase “RANK activity” refers to the biologicalactivity in the cell that occurs after RANK itself has undergoneactivation, that is, after the RANK has become “triggered.” In general,“RANK activity” is instigated by triggering RANK, and the RANK activityis detected by measuring one or more of the biological responses that ischaracteristically induced directly or indirectly by a triggeredwild-type RANK protein. When RANK is triggered, it oligomerizes withother RANK molecules in its immediate vicinity in the cell membrane. If,for example, a RANK-specific agonistic antibody is used to trigger RANK,the antibody brings two RANK molecules into close proximity, thusallowing them to dimerize, thereby triggering RANK activity. It ispossible that more than two RANK molecules will oligomerize when RANK istriggered. Probably, the oligomerization stimulates a conformationalchange in the cytoplasmic tail of the RANK protein, thereby initiating achain of events that results in a discemable biological response.

Triggering RANK is a step required for many of the screening assaysdescribed herein, particularly when it is desired to screen for RANKantagonists. This may be accomplished in many different ways, includingexposure to a RANK-L protein that possesses a RANK binding domain.Full-length RANK-L may be used, such as membrane-bound RANK-L, orsoluble RANK-L molecules, such as the ones described above. At aminimum, the RANK-L polypeptide must be able to bind RANK, thus mustpossess that portion of the RANK-L extracellular region that has thiscapacity. One example of a type of RANK-L useful to stimulate RANKactivity is a leucine zipper fusion of RANK-L, such as the leucinezipper fusion of RANK-L described in U.S. Pat. No. 6,017,729, or otherleucine zipper constructs as described in that reference or elsewhere.

Another example of a type of RANK-L useful to stimulate RANK activity isa FLAG™ poly-His fusion of RANK-L, such as the FLAG™ poly-His fusion ofRANK-L described in U.S. Pat. No. 6,017,729.

RANK can be triggered in a variety of ways, including but not limitedto: over-expression of RANK in a cell; co-expression in the same cell ofRANK and RANK-L; contacting cells expressing membrane-bound RANK withsoluble RANK-L; contacting RANK-expressing cells with cells that expressmembrane-bound RANK-L; and adding agonistic antibodies directed againstRANK to cells that are expressing RANK. In addition to the foregoing,any other desired method of triggering RANK may be used in thehereindisclosed assays.

One preferred method of triggering RANK is to contact RANK responsivecells with agonistic anti-RANK antibodies, i.e., antibodies that bind toRANK and stimulate RANK activity. Examples of agonistic anti-RANKantibodies include anti-human M330 antibodies, anti-human M331antibodies, anti-mouse M395 antibodies, and anti-mouse M396 antibodies.

Yet another way to stimulate RANK activity in RANK responsive cells isto contact RANK responsive cells with one or more cell types expressingRANK-L, such as cells that express RANK-L on their surface or thatsecrete a soluble RANK-L protein. For example, RANK responsive cells canbe co-cultured in liquid or semi-solid medium with one or more celllines expressing RANK-L. Representative examples of cell types thatexpress RANK-L include any cell type that is transfected with a nucleicacid molecule that encodes RANK-L cDNA (either transiently or stably)under conditions that enable the functional expression of RANK-L by thetransfected cells. Additional examples of cell types that express RANK-Linclude primary T-cells (activated with anti-CD3 antibodies), B-cells(such as the 70z3 cell line), and the mouse thymoma cell line EL-4(Anderson et al., Nature 390:175-179 (1997)). In addition, a number ofosteoblast and bone marrow stromal cells of both human and mouse originexpress RANK-L, including ST2 (Yasuda et al., Proc. Nat'l. Acad. Sci USA95: 3597-3602 (1998)) and MC3T3-E1, hMS (Hofbauer et al., J. Bone Min.Res. 15: 2-12, 2000) as well as osteosarcoma cell lines ROS and MG-63(Hofbauer et al., 2000). Expression of RANK-L can be upregulated inthese aforementioned cell types using bone resorbing factors such asglucocorticoids, 1,25-dihydroxyvitamin D3, interleukin 1 (IL-1), IL-6,IL-17, TNFα, prostaglandin E2 or parathyroid hormone (see Hofbauer etal., 2000).

Also, cells which express a soluble RANK-L can be cultured on the solidsurface of a culture well and RANK responsive cells, resuspended insemi-solid medium, are overlaid on top of the RANK-L expressing cells.RANK in these RANK responsive cells becomes triggered by contact withRANK-L that is secreted into and that diffuses throughout the semi-solidmedium.

In some embodiments, the cells expressing RANK-L secrete a soluble formof the molecule. Representative examples of cell types that secretesoluble RANK-L include primary T-cells activated with anti-CD3 and/oranti-CD28 antibodies (Kong et al., Nature 402: 304-309 (1999)), andhuman 293 fibroblasts transfected with a nucleic acid molecule encodingRANK-L (Lacey et al., Cell 93: 165-178 (1998)).

Yet another way of stimulating RANK activity in RANK responsive cells isto overexpress RANK in the RANK responsive cells, for example bygenetically transforming RANK responsive cells with a DNA construct thatincludes a nucleic acid sequence encoding RANK under the control of astrong, constitutive promoter. For example, in the absence ofexogenously added RANK-L, 293/EBNA cells transfected with an expressionvector (pDC409-hRANK) activate NF-κB activity (see, Anderson et al.,1997, supra) and an NF-κB responsive promoter-reporter as a result ofRANK overexpression (see Galibert et al., J. Biol. Chem. 273:34120-27(1998)). The concentration of RANK in the membrane of cellsoverexpressing RANK is so high that RANK spontaneously oligomerizes inthese membranes, thereby triggering RANK activity. Suitable RANK nucleicacids for use in constructs to induce RANK overexpression include DNAscapable of encoding the RANK proteins shown in SEQ ID NOS:2 and 4 (suchDNAs are exemplified by the nucleic acid sequences shown in SEQ ID NOS:1and 3), or variants thereof that encode proteins having at least 85%amino acid sequence homology with a protein according to SEQ ID NO:2 or4, said protein further retaining the ability to trigger RANK activitywhen overexpressed in a cell.

Representative examples of expression vectors that can be used tooverexpress RANK include, but are not limited to: pDC400 series vectors(Giri et al., EMBO J. 13: 2822-2830 (1994)); pDC300 series vectors; theretroviral vector pBMNZ utilizing the Moloney long terminal repeat (LTR)promoters (Kinsella and Nolan, Human Gene Therapy 7: 1405-1413 (1996))or retroviral vectors containing a hybrid tetracycline inducible element(pREVTRE) available from Clontech (1020 East Meadow Circle, Palo Alto,Calif. 94303-4230, USA). These same vectors may be used for introducingRANK or RANK-L DNA into cells when introduction of such DNA may berequired for other aspects of this invention.

Another method of triggering RANK activity is to express in RANKresponsive cells a form of RANK protein which activates one or moreRANK-mediated signaling pathways without binding RANK-L, when expressedat normal levels in the RANK responsive cells, such as FEO RANK (SEQ IDNO:10).

In addition to activation of NF-κB, detectable biological responsesresulting from RANK triggering include, for example, activation of c-srckinase, activation of JNK, differentiation of osteoclast precursors intoosteoclasts, activation of T cells, and so on. C-src is important inproper osteoclast function (see, for example, Lowe et al., Proc NatlAcad Sci USA 90:4485-89 (1993)). In one aspect of the invention, RANKactivity is determined by assessing the amount or level of a reporterprotein expressed by a promoter/reporter construct in which the reportergene is operably linked to a RANK-responsive promoter.

As used herein the term “operably linked” refers to nucleic acidsequences that are functionally related to each other, and thatpreferably are positioned contiguously in a single nucleic acid chain.For example, a regulatory nucleic acid sequence is operably linked to acoding sequence (such as a sequence encoding a reporter protein) if theregulatory nucleic acid sequence controls (either by itself, or inconjunction with one or more other regulatory nucleic acid sequences)the transcription of the coding sequence. Typically, operably linkednucleic acid sequences are contiguous in the same nucleic acid molecule,but in some instances the regulatory sequence may be “trans-acting” andmay be present on a different nucleic acid molecule.

Screening Assays for RANK Agonists and Antagonists:

Semi-solid Medium Assays

In one embodiment of the invention, methods are provided that includethe steps of: (a) contacting RANK responsive cells with a candidatemolecule, the RANK responsive cell being cultured in a semi-solidmedium; and (b) observing an enhanced or reduced rate of colonyformation by the contacted RANK responsive cell in the semi-solidmedium, compared with the rate of colony formation of one or morereference RANK responsive cells that are not contacted with thecandidate molecule. When used to screen for a molecule that antagonizesRANK activity, the methods of this aspect of the invention furtherinclude the step of stimulating RANK activity in the RANK responsivecell.

As used herein the term “semi-solid medium” refers to a cell growthmedium that does not provide a solid substrate to which cells canattach, and that is sufficiently viscous such that cells added to thesemi-solid medium are suspended therein, and are thereby prevented fromsinking through the semi-solid medium and contacting, and attaching to,the inner surface of the container within which the semi-solid medium isdispensed. Semi-solid media useful in the practice of the presentinvention typically include a gelatinization agent (such as agar ormethylcellulose) dissolved in an aqueous medium in an amount of from0.1% to 5% (w/v).

In this embodiment of the invention, RANK-responsive cells are plated ina semi-solid medium in the presence of one or more molecules that is tobe tested for its ability to modulate RANK activity. The cells used inthe practice of this embodiment of the invention express RANK, arecapable of forming colonies in a semi-solid medium, and are stimulatedby RANK activation to differentiate into cell types that grow slowly insemi-solid medium or that cannot grow in semi-solid medium. The testmolecule may be contacted with the cells before or at the time they areplated into the semi-solid medium, or after they have been plated.

In these assays, RANK responsive cells may suspended be in semi-solidmedium that is then applied to the surface of a layer of semi-solidmedium that includes a higher concentration of gelatinization agent thanis present in the semi-solid medium within which the cells aresuspended. For example, RANK responsive cells can be suspended in asemi-solid medium that includes agar at a concentration of 0.3% (w/v).The suspended cells can then be plated onto a layer of semi-solid mediumthat includes agar at a higher concentration, such as a concentration of0.5% (w/v).

An unusual feature of this semi-solid medium approach for detecting RANKantagonists is that a positive response (that is, colony formationand/or colony growth) is enhanced when an antagonist is present, whereasassays to detect antagonists more typically are designed such that themeasured response is abolished in the presence of an antagonist.Moreover, the present assay permits the recovery of cells that areresponding to the antagonist, a feature that is particularly useful whenthe test molecule has been delivered to the cells in the form of arecombinant cDNA library (see below).

Using a semi-solid medium assay, the ability of a test molecule toagonize RANK is detected by contacting RANK-responsive cells with thetest molecule, and observing a reduced rate of colony formation orcolony growth in semi-solid medium as compared with the rate of colonyformation in a reference culture of the same RANK responsive cells thatare not contacted with the test molecule. If desired, for detecting RANKagonists, positive control cultures may be used to provide a referencefor comparison in which the reference cells are contacted with a knownRANK agonist, such as RANK-L or an agonistic anti-RANK antibody.

Cells useful for assays involving semi-solid medium generally includeany cells that express RANK, that are capable of forming colonies in asemi-solid medium, and that are stimulated by RANK triggering todifferentiate into cell types that cannot form colonies in semi-solidmedium. Generally, these cells differentiate into osteoclasts when RANKis triggered. Representative examples of cells useful in the practice ofthis aspect of the invention include the RAW 264.7 cell line (ATCCDeposit Number TIB-51), undifferentiated hematopoietic cells, which maybe obtained from the spleen, peripheral blood or bone marrow cells ofany mammalian species, the BCL-X1/Tag cell line which can differentiateinto osteoclasts that express TRAP, which generally is considered to bean osteoclast-specific enzyme marker (Hentunen et al., J. Clin. Invest.102:88-97 (1998)), and the mouse macrophage-like osteoclast progenitorcell line C7 (Nakagawa et al., Biochem. Biophys. Res. Comm. 253:395-400(1998)). RAW 264.7 cells (a mouse macrophage cell line) are stimulatedto differentiate into multinuclear osteoclasts (which cannot formcolonies in semi-solid media) by the addition of RANK-L.

Colony formation is assessed by visually comparing the size and/ornumber of colonies in cultures contacted with a test molecule with thesize and/or number of reference colonies present in control cultures ofthe same RANK responsive cells that have not been contacted with apotential agonist or antagonist of RANK. The size and/or number ofcolonies is assessed after a desired period of time, such as from 1 to10 days after contacting the RANK responsive cells with the testmolecule, or more preferably, from 5 to 10 days after contacting thecells with the test molecule. Visual comparison of the cultures may bemade, for example, using light or phase contrast microscopy.

Again by way of example, the rate of colony formation can be measuredwithin one culture well using changes in visible light transduction asmeasured spectrophotometrically. In addition, if cells are labeled usinga vital fluorescent dye prior to growth in semi-solid media, the rate ofcolony formation can be assessed fluorometrically. The DNA content ofcells in a culture well can also be measured using standard means toassess the rate of colony formation.

If the aforedescribed semi-solid medium approach is used to detect RANKantagonists, the assay will include a step that comprises activatingRANK in the cells. The cells are contacted with the test molecule (thatis, the putative RANK antagonist) before, during or after the RANKactivation step. RANK activation can be accomplished, for example, byoverexpressing RANK in the cells, or by contacting the cells with anagonistic anti-RANK antibody or with RANK-L. Alternatively, triggeringmay be accomplished by co-expressing RANK-L in the RANK-responsivecells, adding RANK-L to the cultures as soluble RANK-L, or it mayprovided by other means as described herein. If the test molecule is aRANK antagonist, the cells will divide more than in similar cultures towhich the test molecule is not added. If a test molecule that is a RANKantagonist is added prior to RANK triggering, more colonies will appearin cultures that are contacted with the test molecule than in culturesthat are not contacted with the test molecule. If the antagonist isadded after colonies have formed, the colonies exposed to the antagonistwill grow larger than colonies in control cultures that were not exposedto the antagonist.

Using the aforedescribed cells, the ability of a test molecule tofunction as a RANK agonist is detected by contacting the RANK responsivecells with the test molecule, and observing a reduced rate of colonyformation in semi-solid medium as compared with the rate of colonyformation in a control culture of the same RANK responsive cells thatare not contacted with the test molecule. In this assay, a RANK agonistwill stimulate the cells to differentiate into a cell type that cannotform colonies in semi-solid media. Cells typically used for these assayswill differentiate into osteoclasts when exposed to a test molecule thatis a RANK agonist. Control RANK agonists that may be used for theseassays include membrane-bound RANK-L and soluble forms of RANK-L.

In one variation of the semi-solid medium assay, this strategy is usedto screen a nucleic acid library, such as a cDNA library, that encodes apopulation of candidate protein molecules that are being screened fortheir ability to antagonize or agonize RANK activity. The cDNA libraryis introduced into a population of RANK responsive cells by anyart-recognized means, such as by transfection or transduction, asdescribed in more detail below. If RANK antagonists are being sought,cells into which the cDNA molecules have been introduced are cultured ina semi-solid medium, and RANK is triggered in the cells by one of themethods described herein or by another suitable method. The rate ofcolony formation or the rate of colony growth in the suspendedgenetically modified cells is compared with that in similar cells intowhich no DNA other than a control DNA has been introduced. Suitablecontrol cells may receive, for example, vector DNA instead of the cDNAlibrary. Colonies in the genetically modified population which aregrowing significantly faster than colonies in the control population canbe isolated and further studied, The foreign DNA can be retrieved fromsuch colonies to identify and isolate the RANK antagonist that wasresponsible for a colony's enhanced growth. For example, the introducednucleic acid molecules can be isolated from the fast growing coloniesand the nucleic acid sequence of each can be determined. The proteinencoded by the isolated, sequenced, nucleic acid molecule can beexpressed and/or chemically synthesized and its ability to antagonizeRANK activity confirmed and studied.

Agonists of RANK are recognized in this assay by performing the assay asdescribed above but without triggering RANK; cells containing cDNAencoding a RANK agonist will grow more slowly or will fail to formcolonies. cDNA encoding the RANK agonist is recovered from these slowgrowing as described above.

Many different types of mammalian gene transfer and expression vectorshave been developed that are suitable for introducing a cDNA libraryencoding proteins to be tested in the above semi-solid medium assay fortheir ability to modulate RANK activity (see, Miller and Calos, eds.,“Gene Transfer Vectors for Mammalian Cells,” Current Comm. Mol. Biol.,Cold Spring Harbor Laboratory, New York, 1987). Naked DNA can bephysically introduced into mammalian cells by transfection using any oneof a number of techniques including, but not limited to, calciumphosphate transfection (Berman et al., Proc. Natl. Acad. Sci. USA 81:7176, 1984); DEAE-dextran transfection, protoplast fusion (Deans et al.,Proc. Nat'l. Acad. Sci. USA 81: 1292, 1984); electroporation,lipofection (Felgner et al., Proc. Nat'l. Acad. Sic. USA 84: 7413,1987), polybrene transfection (Kawai and Nishzawa, Mol. Cell. Biol. 4:1172, 1984) and direct gene transfer by laser micropuncture of cellmembranes (Tao et al., Proc. Natl. Acad. Sc. USA 84: 4180, 1987).

In addition, various infection techniques have been developed whichutilize recombinant infectious, virus particles for gene delivery. Theviral vectors which have been used in this manner include virus vectorsderived from simian virus 40 (SV40; Karlsson et al., Proc. Nat'l. Acad.Sc. USA 82: 158, 1985); adenoviruses (Karlsson et al., EMBO J 5: 2377,1986); adeno-associated virus (LaFace et al., Virology 162: 483, 1988)and retroviruses (Coffin, 1985, p17-71 in Weiss et al (eds.), RNA TumorViruses, 2nd ed., Vol. 2. Cold Spring Harbor Laboratory, New York).These same virus vectors may be used for introducing RANK or RANK-L DNAinto cells when introduction of such DNA may be required for otheraspects of this invention.

Gene transfer and expression methods are numerous and essentiallyfunction to introduce and express genetic material in mammalian cells.Several of the above described techniques have been used to transducehematopoietic or lymphoid cells, including calcium phosphatetransfection (Berman et al., supra, 1984); protoplast fusion (Deans etal., supra 1984); electroporation (Cann et al. Oncogene 3: 123, 1988)and infection with recombinant adenovirus (Karlsson et al., supra;Ruether et al. Mol. Cell Biol. 6: 123, 1986); adeno-associated virus(LaFace et al., supra); and, retrovirus vector (Overell et al., Oncogene4: 1425, 1989). Primary T lymphocytes have been successfully transducedby electroporation (Cann et al., supra, 1988) and by retroviralinfection (Nishihara et al., Cancer Res 48: 4730, 1988); Kasid et al.,supra, 1990).

Assays involving the aforedescribed semi-solid medium screening strategyare useful as follows for screening collections of molecules, such aslibraries of small organic molecules or peptides. Microtiter plates,such as 96-well microtiter plates, may be used, and a differentcandidate agonist or antagonist of RANK activity is placed in each welltogether with an aliquot of RANK-responsive cells in semi-solid medium.Cells used for this assay are cells that normally will differentiate andstop dividing in response to RANK triggering (see above for descriptionof suitable cells). If it is desired to detect molecules with RANKantagonist activity, a stimulus for triggering RANK is provided, such asRANK-L, which may be added to the medium or which may be provided bysome other means as described herein. Again by way of example, acandidate molecule can be dissolved and distributed throughout thesemi-solid medium, or can be applied (in solution form) to the uppersurface of the semi-solid medium and allowed to diffuse throughout.

If desired, the nucleic acid molecules introduced into the RANKresponsive cells can be stably integrated into the RANK responsive cellgenome. For example, a cDNA library constructed in a retroviral vectorcan be utilized to transfect a RANK responsive cell line. The advantageof stably integrating the introduced DNA molecules into the genome ofthe RANK responsive cells is that a continuous, high level of geneexpression is typically obtained. Example 2 herein discloses arepresentative protocol for screening for agonists or antagonists ofRANK signaling using RAW 264.7 cells and a retroviral expressionlibrary.

Another application of the methods of the invention is to screen formolecules (such as cDNAs, proteins and peptides) that complement adefective RANK signal. For example, a form of human RANK (termed“RANKΔ340-421”) in which the TRAF6 binding site is missing, cannotstimulate the formation of osteoclasts from hematopoictic precursorcells. This form of RANK is described in Galibert et al., J. Biol. Chem.273:34120, 1998, has an amino acid sequence corresponding to that ofhuman RANK (SEQ ID NO:2) but with the TRAF6 binding site (amino acids340-421 of SEQ ID NO:2) deleted. The methods of the present inventioncan therefor be used to screen for molecules that complement theRANKΔ340-421 signaling mutation and thereby permit the formation ofosteoclasts from hematopoietic precursor cells. Example 3 hereindescribes the preparation of RANK responsive cell line that expressesRANKΔ340-421.

Promoter/Reporter Assays Using the MMP-9 or TRAP Promoter

In a further aspect of the invention, provided herein are screeningassays that use promoter/reporter constructs that employ promoters thatwere not previously known to be capable of responding to RANK activationby causing elevated expression of protein coding sequences to which thepromoters are operably linked. Specifically, the presentpromoter/reporter constructs use a promoter derived from a TRAP gene orfrom a MMP-9 gene. Example 4 herein describes a construct of the murineMMP-9 promoter (Sato et al., J Biol Chem 268:23460-68 (1993); Sato andSeiki, Oncogene 8:395-405 (1993)) fused to the human IL-2α receptor. Thehuman MMP-9 promoter or a TRAP promoter (human or murine; see, forexample, Reddy et al., Bone 16:587-593 (1995))also can be used for thesescreening methods.

Assays according to this aspect of the invention include the steps of:(a) contacting a cultured RANK responsive cell with a test molecule, theRANK responsive cell comprising a nucleic acid molecule encoding areporter molecule, the nucleic acid molecule encoding a reportermolecule being operably linked to a RANK responsive regulatory nucleicacid sequence; and (b) observing an enhanced or reduced level ofexpression of the reporter molecule in the contacted RANK responsivecell, compared to the level of expression of the reporter molecule inone or more reference RANK responsive cells that are not contacted withthe candidate molecule. When used to screen for a molecule thatantagonizes RANK activity, the methods of this aspect of the inventionfurther comprise the step of stimulating RANK activity in the RANKresponsive cell.

RANK agonists are identified in this type of assay is detected byobserving an increased level of reporter molecule expression in RANKresponsive cells contacted with the RANK agonist as compared to thelevel of reporter molecule expression in control RANK responsive cellsthat have not been contacted with the RANK agonist, or with any otheractivator of RANK activity. The control cells are typically the sametype of RANK responsive cells as the RANK responsive cells contactedwith the RANK agonist. When the assays are directed to identifying RANKagonists, the protocol does not include a RANK triggering step such asdeliberately contacting the cells with RANK-L. The presence of a RANKantagonist is detected by observing a reduced level or the absence ofreporter molecule expression in RANK responsive cells in which RANK hasbeen triggered and which have been contacted with a candidateantagonist. The level or reporter expression is assessed by comparisonwith the level of reporter expression in control, RANK responsive cellsthat have been contacted with a RANK activator, but which have not beencontacted with the candidate RANK antagonist. The control cells aretypically the same type of RANK responsive cells as the RANK responsivecells contacted with the RANK antagonist.

When this type of assay is used to screen for antagonists of RANKactivity, RANK activity must be stimulated in the RANK responsive cells.Typically, RANK activity is triggered before or at the same time ascontacting the RANK responsive cells with the candidate molecule(s). Insome cases, it may be desirable to stimulate RANK activity aftercontacting the RANK responsive cells with the candidate molecule. Anyprocedure that stimulates RANK activity can be utilized, such as thoseprocedures for stimulating RANK activity that are described above.

Cells useful in this aspect of the invention express RANK protein andinclude at least one signal transduction pathway that is stimulated bythe activation of RANK. Some cells useful in this aspect of theinvention naturally express RANK and include at least one signaltransduction pathway that is stimulated by the activation of RANK.Examples of this type of cell include RAW 264.7 cells, the BCL-X1/Tagosteoclast cell line which can be differentiated into TRAP+osteoclasts(Hentunen et al., J. Clin. Invest. 102: 88-97 (1998)), and the mousemacrophage-like osteoclast progenitor cell line C7 (Nakagawa et al.,Bioch. Biophys. Res. Comm. 253: 395-400 (1998)).

Other cells useful in this aspect of the invention are geneticallymodified to express RANK and/or to include at least one signaltransduction pathway that is stimulated by the activation of RANK.Examples of this latter type of cell include 293/EBNA cells. Virtuallyany cell type capable of growth in culture may be genetically modifiedto express RANK for the purposes of these assays. Numerous othersuitable methods for introducing RANK DNA into a cell are describedelsewhere in this disclosure, and include viral vectors and othermethods such as electroporation, lipofection and so on.

The RANK-responsive cells can be contacted with one or more candidatemolecules in any acceptable manner, such as by utilizing thoseprocedures that are described above or by any other desired method.

Reporter molecules that are useful in this embodiment of the inventioninclude luciferase, β-galactosidase, green fluorescent protein, alkalinephosphatase and any heterologous surface protein which can be detectedon the surface of a RANK responsive cell, such as by using a specificantibody directed against the heterologous protein. Examples of usefulheterologous surface proteins include the human IL-2 receptor, themurine IL-4 receptor (abbreviated as mIL-4R), the human CD2, CD4 or CD8proteins.

Assays Based on Detecting c-src Activity or F-actin Rings

In another aspect of the invention, assays are provided for screeningfor a molecule RANK and RANK-L antagonists by measuring the extent towhich a candidate molecule enhances or inhibits the RANK-mediatedinduction of c-src tyrosine kinase activity and/or F-actin ringformation. F-actin rings are cytoskeletal structures that arecharacteristic of active osteoclasts (Lakkakorpi and Vaananen, J. BoneMin. Res. 6:817-26 (1991)).

To detect F-actin rings, cells are fixed, such as by exposure to 3%paraformaldehyde, and visualized by staining cells with a fluorescentprobe that binds specifically with actin. A suitable fluorescent tag isphalloidin, which can be obtained from Molecular Probes, Eugene, Oreg.The fluorescent signal is detected, for example, using a standardfluorescent microscope, and the number of cells having F-actin rings isvisually quantified. An F-actin ring is identified as a continuous ringof F-actin at the periphery of a cell, and these distinct structures arevisible through a microscope. F-actin rings do not appear in cell typesother than osteoclasts.

To detect c-src activity, phosphotransferase activity of this enzyme ismeasured using a synthetic substrate, such as the p34/cdc2 peptide(KVEKIGEGTYGVVYK) (SEQ ID NO:13), which functions as a substrate for theenzyme. An exemplary assay for measuring c-src activity is provided inExample 8.

This aspect of the invention utilizes cells that express a RANK proteinthat is capable of activating the cells to differentiate intoosteoclasts, or any cells that respond to RANK triggering by activatingc-src activity. In a preferred embodiment of this aspect of theinvention, the RANK protein induces elevated levels of c-src tyrosinekinase activity and F-actin ring formation while the cells areundergoing differentiation. Exemplary cells useful in this embodimentare any cells that are capable of differentiating into osteoclasts inresponse to RANK triggering and that also express a form of RANK that iscapable of inducing c-src activity and F-actin ring formation. Suchcells include primary hematopoietic cells that have been enriched forosteoclast precursors, or a cell line such as RAW 264.7 cells. Suitableprimary hematopoietic precursors can be derived from bone marrow cells,fetal liver or peripheral blood. Suitable cells also include cells thathave been genetically modified to express RANK, using the methodsdescribed above.

For this type of assay, the test molecule may be added to the culturemedium for up to about five days after differentiation is complete.C-src activity or F-actin ring formation is assayed after the cells havebeen exposed to the test molecule for any convenient time period. Forexample, the activity is measured after 6 to 12 hours, after one day,after two days, after three days, after four days, after five days orafter a longer period of exposure. A test molecule is identified asbeing a RANK agonist if after exposure to the test molecule the amountof F-actin rings or c-src activity detected in the cells is increased ascompared with the level observed in control RANK−/−cells into which noRANK DNA was introduced.

In this type of assay, test molecules also may be evaluated for theirability to complement certain biological activities that arecharacteristic of the wild-type RANK protein. Generally, this type ofassay exploits the fact that wild-type RANK protein can induce c-srcactivity and F-actin ring formation in cells that are undergoing theprocess of differentiating into osteoclasts. However, these twoactivities of RANK can be abrogated by deleting the TRAF6 binding domainfrom the RANK protein (see Example 8), although the TRAF6 binding domainis not required in order for RANK activation to be able to induceosteoclast differentiation. Thus, when TRAF6 deletion mutants of theRANK protein are expressed in osteoclast precursors, triggering RANKwill cause the cells to differentiate, but will not cause them toexpress higher levels of c-src activity nor will these cells exhibitF-actin rings. For human RANK protein, the TRAF6 binding domain isencompassed within a region defined by amino acids 340-421 of SEQ IDNO:2. Thus, cells in which such RANK mutants are expressed can be usedin assays to screen for molecules capable of complementing the TRAF6binding site deletion in the mutant RANK. The ability of a test moleculeto complement this defect is detected by observing that when the testmolecule is contacted with cells expressing the RANK mutant, c-srcactivation and F-actin formation do occur when RANK is triggered.

Cells suitable for use with TRAF6 mutants of RANK include primaryhematopoietic precursor cells from RANK knock-out animals, such as thepreviously described RANK−/−mice (Dougall et al., 1999). To perform thisassay, cells from a RANK knock-out animal are genetically modified byintroducing a DNA encoding a mutant RANK protein that lacks a TRAF6binding region. Exemplary DNAs for this purpose are mouse or human RANKDNA from which the TRAF6 binding domain coding sequences have beendeleted. Suitable means for introducing the RANK DNA include infectionwith a viral vector (such as a retroviral or adenovirus vector) intowhich the DNA encoding the protein has been ligated, or any of the othermeans discussed above. After introducing the RANK mutant DNA, the cellsare induced to differentiate into osteoclasts by triggering the RANKprotein using any of the means of RANK triggering that are describedabove or any other desired means of triggering RANK. To determine if atest molecule complements the defect in this mutant form of RANK, themolecule is added to the culture medium for part or all of theincubation period during which the cells are undergoing differentiation.

Screening Assays Involving CaPO₄ Resorption

Provided also are methods of screening for RANK agonists or antagonistsin assays based on the RANK-dependent resorption of a synthetic matrixof calcium phosphate. Wild-type RANK protein can enable cells todifferentiate into osteoclasts that are capable of resorbing calciumphosphate (CaPO₄), while signals from a RANK protein lacking a TRAF6binding site do not initiate CaPO₄ resorption. Cells useful for thisscreening assay include any cells in which the activation of RANK leadsto CaPO₄ resorption, that is, cells that differentiate into osteoclastswhen RANK is triggered. Exemplary cells for use in this assay includeprimary hematopoietic precursors, primary hematopoietic cells, RAW 264.7cells, or any cell transfected with a form of RANK that supports thisactivity (such as osteoclast precursor cells from RANK−/−mice).

In one embodiment of the invention, this method is used to screen formolecules that complement inactive RANK mutants, such as the TRAF6deletion mutants as described above.

Suitable procedures for performing this assay are exemplified by thoseset forth in Example 9. Generally, cells are cultured on commerciallyavailable thin microscope slides that are thinly coated with CaPO₄ RANKresponsive cells so grown will respond to RANK triggering bydifferentiating into cells that resorb CaPO₄, resulting in the formationof a discrete pit in the CaPO₄ film. To detect a RANK antagonist, thenumber of pits on slides contacted with the test molecule is comparedwith the number of pits on slides not contacted with the test molecule.

RANK agonists are detected in this type of assay by growing suitablecells on CaPO₄ films and contacting the cells with a test moleculewithout first triggering RANK in the cells.

The following examples illustrate the best mode now contemplated forpracticing the invention, but should not be construed to limit theinvention.

EXAMPLE 1

This example describes evaluating murine 3T3 cells transfected withplasmids containing DNA encoding human FEO RANK (SEQ ID NO:9), andmurine 3T3 cells expressing recombinant DNA encoding human wild typeRANK (SEQ ID NO:1) for their relative ability to activate endogenousc-jun kinase (JNK) in the absence of RANK-L stimulation. JNK is known tobe activated as a consequence of RANK signal transduction.

For JNK assays, whole cell extracts were prepared from 3T3 cells 24hours after transfection. Cells were lysed in a buffer containing 20 mMHEPES, pH 7.4, 2 mM EGTA, 50 mM β-glycerol phosphate, 1 mM DTT, 1 mMsodium orthovanadate, 1% Triton-X 100, 10% glycerol and the proteaseinhibitors leupeptin, pepstatin A, and PMSF. Clarified lysates wereimmunoprecipitated with 1 μg each anti-JNK (FL) and anti-JNK (C17)antibodies (both from Santa Cruz Biotechnology, Inc. Santa Cruz,Calif.). The immune complexes were washed three times in lysis buffer,two times with wash buffer (500 mM LiCl, 100 mM Tris, pH 7.5, 0.1%Triton X-100, 1 mM DTT) and three times in assay buffer (20 mM MOPS, pH7.0, 2 mM EGTA, 10 MM MgCl₂, 1 mM DTT, 0.1% Triton X-100). JNK activitywas determined by an immune-complex assay using 1 μg of a fusion proteinof glutathione-S-transferase and amino acids 1-169 of c-jun kinase(GST-cJun (1-169)) (UBI, Lake Placid, N.Y.) and 5 μCi of [³²P]-ATP assubstrate in 40 μl of assay buffer at 30° C. for 20 min. Reactionproducts were resolved on 4-20% SDS/PAGE and visualized byautoradiography.

JNK was activated in response to expression of FEO RANK, but not inresponse to expression of wild type RANK.

EXAMPLE 2

This example describes screening for antagonists of RANK signaling usingRAW 264.7 cells and a retroviral expression library in a semi-solidmedium assay.

A retroviral cDNA library is constructed in pBMNZ. Preferably the cDNAis synthesized against mRNA isolated from cells that do not formosteoclasts, i.e., cells that may express antagonists of RANK activity(e.g., macrophages activated with GM-CSF or IL-10). Retroviral particlesare packaged using the Phoenix cell lines (provided by Dr. Gary Nolan,Stanford University, USA) and appropriate envelope protein (such asecotropic envelope protein, amphotropic envelope protein or polytropicenvelope protein). For example, in the case of transiently producedretroviral vectors, Phoenix packaging cells are transfected withconstructs generated in the pBMNZ retroviral vector, and the culturesupernatant is harvested 48 hrs post-transfection. The retroviralparticles are isolated using standard techniques. For example, viralparticles are purified from membrane fragments by sterile filtrationthrough a 0.45 micron filter.

RAW 264.7 cells are infected with the packaged retroviral cDNA libraryunder conditions which lead to optimal infection. For example, optimalinfection conditions can be determined by monitoring the expression of areporter gene expressed from a test retroviral construct. Retroviralconstructs encoding β-galactosidase (e.g., pBMNZ/LZRS; Kinsella andNolan, 1996, supra) can be used to produce retroviral particles. Afterinfection of cells with a serial dilution of the virus stocks, thenumber of β-galactosidase expressing cells can be monitored 24 hr afterinfection. Various conditions including the choice of envelope protein,multiplicity of infection, length of infection incubation time,pre-treatment of cells under conditions to promote cell-cycling,co-factors such as polybrene or recombinant fibronectin fragments can bevaried in order to determine the conditions under which the largestamount of test virus enters the cells.

Cells are then plated in a semi-solid medium after the appropriate timeallowing for expression of cDNAs in the infected cells. Exemplaryconditions for plating infected cells are plating, in each well of a24-well plate, 3 ml of 0.3% (w/v) methylcellulose medium containinginfected cells at a cell density of from 1×10⁵ cells/ml to 1×10⁶cells/ml. A soluble leucine zipper form of RANK-L (200 ng/ml) isincluded in the semi-solid medium.

Cells are cultured for a period of from 5 days and 8 days and coloniesderived from the infected cell population that are growing significantlyfaster than the colonies derived from the uninfected, control populationare isolated for further analysis. For example, the colonies of interestare aseptically isolated and grown further in the absence of RANKactivation in order to increase the cell numbers. The cDNA clone withinthe cells of each colony is recovered by any art-recognized technique,such as RT-PCR of the expressed viral transgene, PCR of the incorporatedprovirus or via a helper viral recombination and recovery of viralparticles. For example, amplification of integrated cDNAs has beendescribed by Kitamura et al., Proc. Natl. Acad. Sci. USA 92: 9146-9150(1995).

A variation of this assay takes advantage of the cell-fusion andterminal differentiation that occurs when RAW264.7 cells are contactedwith RANK-L. To perform this variation of the assay, RAW264.7 cells areplated in a 6 well culture plate, a soluble leucine zipper form ofRANK-L is added to the wells, and the plates are incubated for 3 to 5days in the presence of the leucine zipper RANK-L polypeptide. Cellsthat respond positively to the RANKL trigger will fuse into largemultinuclear differentiated osteoclasts and will lose their potential todivide in culture. If desired, other forms of RANKL besides leucinezipper RANKL can be used as the stimulus in this assay. To use thisassay to test various agents for their capacity to antagonize RANK, theputative antagonist is added to the wells prior to and/or duringexposure to the RANKL stimulus. If a candidate antagonist, such as anexpressed cDNA, abrogates the cells' responsiveness to RANK-L, the cellswill retain their capacity to divide in these cultures. Cells from theseplates that remain capable of growth in culture can be separated andrecovered from the fused differentiated osteoclasts by vigorouspipetting or by trypsin digestion. These recovered cells will be able togrow in normal growth media in the absence of RANKL, thus they can beenumerated and propagated using conventional techniques. As describedabove, the cDNAs within the propagated cells are recovered byconventional techniques, such as reverse-transcriptase PCR of theexpressed viral transgene, PCR of the incorporated provirus or via ahelper viral recombination and recovery of viral particles.

EXAMPLE 3

This example describes the preparation of RANK responsive cell line thatexpresses RANKΔ340-421 (see Galibert et al., 1998 for description ofRANKΔ40-421).

Spleen cells were isolated from 3-6 week old RANK−/−mice (which have adefect in osteoclast formation and are osteopetrotic) and lineagedepleted in the following manner. T-cells were removed byimmunoabsorption using biotinylated anti-CD3 antibodies; erythroid cellswere removed by immunoabsorption using biotinylated anti-Ter-119antibodies; and granulocytes were removed by immunoabsorption usingbiotinylated anti-GR-1 antibodies. The antibody-cell complexes wereremoved by binding the biotin moiety to streptavidin-conjugated magneticbeads, which were then passed over a metallic MACS depletion column.

The lineage depleted cells were then incubated for 48 hrs in 40 ng/mlCSF-1 and infected using retroviral supernatants (MOI of 5) in thepresence of recombinant fibronectin fragments (Retronectin, PanVeraCorp, Madison, Wis.) for an additional 48 hr in 40 ng/ml CSF-1.Following infection, spleen cells were harvested and plated in MEM 10%FBS containing 40 ng/ml CSF-1 and 200 ng/ml murine RANK-L. Cells werethen cultured under these conditions for 5 days to allow differentiationof osteoclasts.

The retroviruses used for transfection were prepared by subcloning DNAencoding RANKΔ340-421 into the pBMNZ vector (Kinsella and Nolan, 1996,Human Gene Therapy 7:1405-1413). The entire RANKΔ340-421 cDNA wasexcised from pDC304/RANKΔ340-421 (Galibert et al., J. Biol. Chem.273:34120, 1998) using the restriction endonucleases Bgl II and Not I.This cDNA insert fragment was ligated into the retroviral vector pBMNZ(Kinsella and Nolan, 1996, supra) that had been digested with Bam HI andNot I. The resultant plasmid was purified, the DNA sequence confirmedand designated pBMNZ/RANKΔ340-421. Production of infectious retroviralvector particles in 293-E Phoenix packaging cells was performed asdescribed (Kinsella and Nolan, 1996, supra).

EXAMPLE 4

This example describes the preparation of promoter/reporter vectors ofthe murine MMP-9 promoter (SEQ ID NO:11) fused to the human IL-2αreceptor.

A DNA fragment containing the promoter region of the murine MMP-9 genewas fused to a cDNA molecule encoding the human IL-2α receptor asfollows. A plasmid containing 4.15 kb of the murine MMP-9 promoterregion (SEQ ID NO:11) was subcloned into the promoter deficient pGL2basic vector (Promega, Madison, Wis.) containing the luciferase reportergene as described by Roach et al., Gene 208: 117-122 (1998). Theresultant plasmid was designated pGB-colNK1. An approximately 3.5 kb SmaI/EcoRI fragment containing the MMP-9 5′ flanking promoter sequence (SEQID NO:11) was excised from pGB-colNK1 and subcloned into the SINretroviral vector pSIR (Clontech) at the Barn HI site which had beenmade blunt-ended.

A cDNA encoding the human IL-2α receptor was subcloned into CAVNOT asdescribed in Cosman, D., et al. “Cloning and expression of human andmouse 1L-2 receptor cDNAs”. In: Lymphokines: Molecular Cloning andAnalysis of Lymphokines. D. R. Webb and D. V. Goeddel (eds.) AcademicPress, 1987, p. 109.

The human IL-2α receptor cDNA was amplified from the CAVNOT constructusing PCR such that the 5′ end was modified to include a Bgl II site andthe 3′ end was modified to include a PflM1 site. This amplified productwas ligated into the pGEM-T vector (Promega). The human IL-2α receptorcDNA was excised from this plasmid using Bgl II and PflM1 restrictionsites and ligated into pGL2 basic (Promega) which had been digested withBgl II and PflM1 to excise the luciferase reporter cDNA. The human IL-2αreceptor thus replaced the luciferase reporter in pGL2, and theresulting plasmid was designated pGL2/hIL-2 receptor.

The pGL2/hIL-2 receptor was digested with KpnI and Bgl II within thepolylinker upstream of the cDNA encoding human IL-2α receptor. A 3.5 kbKpn I/NheI fragment isolated from the pGB-colNK1 plasmid encoding theMMP-9 promoter (SEQ ID NO:11) and the contiguous Nhe I to Bgl II (653bp) fragment of the remaining MMP-9 promoter were ligated in atrimolecular ligation with the pGL2/hIL-2 receptor forming the plasmidtermed pGL2-MMP-9/human IL-2 receptor in which the entire 4.15 kb 5′flanking sequence of the mouse MMP-9 flanking region is fused directlyupstream of the hIL-2α receptor cDNA. This construct exhibitedresponsiveness to RANK.

In order to test the inhibitory activity of a candidate molecule usingthis system, the candidate molecule may be added prior to, simultaneouswith or after addition of the RANK activity agonist. The level of IL-2αreceptor expression on the surface is a measure of the level of RANKactivation.

The location of the RANK-responsive portion of MMP-9 promoter was morenarrowly identified by testing further truncations of the promoter. APVUII/BGL2 restriction fragment including the 5′-proximal 1822 bp of theMMP-9 promoter was fused with a BLGII/EcoRI restriction fragmentencoding the human IL-2 receptor α in the multicloning site of the pSIRretroviral vector (Clontech). The resulting plasmid, which was namedpSIR/MMP-9, is responsive to RANK and is useful in assays to identifyRANK antagonists. The region of the MMP-9 promoter present in pSIR/MMP-9corresponds to nucleotides 1769-3591 of SEQ ID NO:11.

pSIR/MMP-9 was introduced into RANK responsive cells as follows.Retroviral particles were prepared after transfection of 293/E packagingcells with pSIR/MMP-9. RAW264.7 cells were infected with these particlesand neomycin resistant colonies stably expressing the reporter wereisolated. Treatment of these cells with RANKL led to an increase in thecell surface expression of the hIL-2 αR, as detected by flow cytometryusing the mouse mAb (clone 2A3) anti-human IL-2 αR as a reagent fordetecting the IL-2R. Expression of hIL-2α receptor was observed within 4hours and reached the maximal level observed within 48 hr.

Surface expression of human IL-2α receptor is detected by flow cytometryin the following manner. Cells are harvested and known, specific,antibody binding sites are blocked using a solution of PBS containing 5%normal goat serum for 30 minutes at 4° C. Cells are then washed andincubated with the anti-human IL-2α receptor monoclonal antibody clone,at an antibody concentration of 5 μg/ml for 1 hour at 4° C. Followingthis incubation, cells are washed and a fluorescently conjugated,anti-mouse IgG secondary antibody is incubated with the cells for anadditional thirty minutes at 4° C. After washing the cells, thefluorescence intensity is measured using a flow cytometer, such as aFACS scan (Becton Dickinson).

Additionally, surface expression of human IL-2α receptor can be analyzedusing a radioactive antibody against IL-2α receptor. For themIL-4R-specific radioimmune assay, mouse anti-human IL-2α monoclonalantibody reactive with mIL-4R was labeled with ¹²⁵I via a Chloramine Tconjugation method; the resulting specific activity is typically1.5×10¹⁶ cpm/nmol. After 48 hours, cells transfected withpGL2-MMP-9/human IL-2 receptor were washed once with media (DMEM, 12 5%FBS). Non-specific binding sites were blocked by the addition ofpre-warmed binding media containing 5% non-fat dry milk and incubationat 37° C./5% CO₂ in a tissue culture incubator for one hour. Theblocking media was decanted and binding buffer containing ¹²⁵Ianti-mIL-4R (clone M1; rat IgG1) was added to the cells and incubatedwith rocking at room temperature for 1 hour. After incubation of thecells with the radio-labeled antibody, cells were washed extensivelywith binding buffer (2×) and twice with phosphate-buffered saline (PBS).Cells were lysed in 1 ml of 0.5M NaOH, and total radioactivity measuredwith a gamma counter. Using this assay, 293/EBNA co-transfected withDNAs encoding RANK demonstrated transcriptional activation, as shown bydetection of muIL-4R on the cell surface. Overexpression of RANKresulted in transcription of muIL-4R, as did triggering of the RANK byRANK-L. Similar results are observed when RANK is triggered by agonisticantibodies.

Further, cells expressing human IL-2α receptor on their surface can beisolated using a panning technique, such as the technique described byAruffo and Seep, PNAS 84:8573-8577 (1987). In brief, a secondaryantibody which recognizes the primary antibody is immobilized ontobacteriological 60 millimeter plates. The cells to be panned areprepared as single cell suspensions in PBS containing 0.5 mM EDTA and 5%FBS. The antibody to the cell-surface marker is added at approximately 5μg/ml followed by incubation on ice for 30 minutes. Cells are washedonce and added to the second antibody-coated plates in PBS/EDTA/5% FBS,and incubated at room temperature for 1-3 hours. Excess cells notadhering to the dish are removed by gentle washing with PBS/5% FBS.

EXAMPLE 5

This example describes the activation of the TRAP promoter. A 2.6 kb DNAfragment containing the human TRAP promoter was obtained by digestingthe plasmid pBL2HT2.2 with the restriction endonuclease ApaI. Thecloning of the human TRAP gene 5′ region and the construction ofpBL2HT2.2 are fully described in Reddy et al. (Bone 16:587-593 (1995)).A DNA containing the mouse TRAP promoter (SEQ ID NO:12) and a DNAcontaining the murine MMP-9 promoter (SEQ ID NO:11) also were used forthese experiments. DNAs containing the promoters were fused to theluciferase reporter gene. These promoter/reporter constructs weretransfected into human 293/EBNA cells along with various combinations ofexpression vectors that encoded full-length human RANK (SEQ ID NO:2) andhuman full-length RANK-L proteins (SEQ ID NO:6).

For the mouse TRAP promoter (SEQ ID NO:12), 2×10⁵ 293/EBNA cells weretransfected using DEAE/dextran with 40 ng of a plasmid encodingapproximately 2 kb of the mouse TRAP promoter (SEQ ID NO:12) fused to aluciferase reporter, 20 ng of an expression vector encoding RANK-L (SEQID NO:6), and 0.4 ng of an expression vector encoding RANK (SEQ IDNO:2). Twenty four hours after transfection, luciferase activity in celllysates was measured according to manufacturer's instructions (Promega)using a EG&G/Berthold luminometer. Expression of RANK was sufficient toincrease reporter expression (approximately 2-fold) while thecombination of RANK (SEQ ID NO:2) and RANK-L (SEQ ID NO:6) increasedreporter expression approximately 4-fold.

For the human TRAP promoter, the 1.9 kb ApaII fragment containing thepromoter activity isolated from the region upstream of the human TRAPgene (Reddy et al., 1995) was fused to a luciferase reporter andtransfected (40 ng) into 293/EBNA cells. The combination of human RANK(SEQ ID NO:2) and human RANK-L (SEQ ID NO:6) increased reporterexpression approximately 1.5 fold.

For the murine MMP-9 promoter experiments, 4.1 kb of the murine MMP-9promoter (SEQ ID NO:11) were fused to a luciferase gene and transfected(40 ng) into 293/EBNA cells. Transfection of either RANK (SEQ ID NO:2)alone or the combination of RANK (SEQ ID NO:2) plus RANK-L (SEQ ID NO:6)increased reporter expression 2.5-fold.

Additionally, RAW 264.7 cells (6×10⁶ cells) were transfected with 15 μgof MMP-9(SEQ ID NO:11)/luciferase plasmid DNA using DEAE/dextran. Twohours after transfection, cells were divided into two equal amounts andfurther incubated for 24 hours. Addition of 1 μg/ml of a leucine zipperform of murine RANK-L for 18 hours was sufficient to induce theMMP-9(SEQ ID NO:11)/luciferase promoter 10-15 fold.

Quantitative RT-PCR measurements of mouse TRAP and mouse MMP-9 mRNA inRAW 264.7 cells after treatment with either mouse RANKL/LZ (200 ng/ml)or TNFα (20 ng/ml) for various times revealed that TRAP mRNA is elevatedgreater than 250-fold by RANK-L, but is only increased by about 2.3-foldby TNFα. MMP-9 mRNA is elevated greater than 350-fold by RANK-L, but isnot increased by TNFA. This specificity is helpful in screening forinhibitors of RANK signal transduction.

EXAMPLE 6

This example illustrates the preparation of monoclonal antibodiesagainst RANK-L. Preparations of purified recombinant RANK-L, forexample, or transfixed cells expressing high levels of RANK-L, areemployed to generate monoclonal antibodies against RANK-L usingconventional techniques, such as those disclosed in U.S. Pat. No.4,411,993, incorporated herein by reference. DNA encoding RANK-L canalso be used as an immunogen, for example, as reviewed by Pardoll andBeckerleg in Immunity 3: 165, 1995. Such antibodies are likely to beuseful in interfering with RANK-L signaling (antagonistic or blockingantibodies), as components of diagnostic or research assays for RANK-Lor RANK-L activity, or in affinity purification of RANK-L.

To immunize rodents, RANK-L immunogen is emulsified in an adjuvant (suchas complete or incomplete Freund's adjuvant, alum, or another adjuvant,such as Ribi adjuvant R700 (Ribi, Hamilton, Mont.), and injected inamounts ranging from 10-100 μg subcutaneously into a selected rodent,for example, BALB/c mice or Lewis rats. DNA may be given intradermally(Raz et al., Proc. Natl. Acad. Sci. USA 91: 9519, 1994) orintramuscularly (Wang et al., Proc. Natl. Acad. Sci. USA 90: 4156,1993); saline has been found to be a suitable diluent for DNA-basedantigens. Ten days to three weeks days later, the immunized animals areboosted with additional immunogen and periodically boosted thereafter ona weekly, biweekly or every third week immunization schedule.

Serum samples are periodically taken by retro-orbital bleeding ortail-tip excision for testing by dot-blot assay (antibody sandwich),ELISA (enzyme-linked immunosorbent assay), immunoprecipitation, or othersuitable assays, including FACS analysis. Following detection of anappropriate antibody titer, positive animals are given an intravenousinjection of antigen in saline. Three to four days later, the animalsare sacrificed, splenocytes harvested, and fused to a murine myelomacell line (e.g., NS1 or preferably Ag 8.653 [ATCC CRL 1580]). Hybridomacell lines generated by this procedure are plated in multiple microtiterplates in a selective medium (for example, one containing hypoxanthine,aminopterin, and thymidine, or HAT) to inhibit proliferation ofnon-fused cells, myeloma-myeloma hybrids, and splenocyte-splenocytehybrids.

Hybridoma clones thus generated can be screened by ELISA for reactivitywith RANK-L, for example, by adaptations of the techniques disclosed byEngvall et al., Immunochem. 8: 871 (1971) and in U.S. Pat. No.4,703,004. A preferred screening technique is the antibody capturetechnique described by Beckman et al., J. Immunol. 144: 4212 (1990).Positive clones are then injected into the peritoneal cavities ofsyngeneic rodents to produce ascites containing high concentrations (>1mg/ml) of anti-RANK-L monoclonal antibody. The resulting monoclonalantibody can be purified by ammonium sulfate precipitation followed bygel exclusion chromatography. Alternatively, affinity chromatographybased upon binding of antibody to protein A or protein G can also beused, as can affinity chromatography based upon binding to RANK-Lprotein. Using the methods described herein to monitor the activity ofthe mAbs, both blocking (i.e., antibodies that bind RANK-L and inhibitbinding to RANK) and non-blocking (i.e., antibodies that bind RANK-L anddo not inhibit binding) are isolated.

EXAMPLE 7

This example illustrates the preparation of monoclonal antibodiesagainst RANK. Preparations of purified recombinant RANK, for example, ortransfected cells expressing high levels of RANK, are employed togenerate monoclonal antibodies against RANK using conventionaltechniques, such as those disclosed in U.S. Pat. No. 4,411,993. DNAencoding RANK can also be used as an immunogen, for example, as reviewedby Pardoll and Beckerleg in Immunity 3: 165, 1995.

To immunize rodents, RANK immunogen is emulsified in an adjuvant (suchas complete or incomplete Freund's adjuvant, alum, or another adjuvant,such as Ribi adjuvant R700 (Ribi, Hamilton, Mont.), and injected inamounts ranging from 10-100 μg subcutaneously into a selected rodent,for example, BALB/c mice or Lewis rats. DNA may be given intradermally(Raz et al., Proc. Natl. Acad. Sci. USA 91: 9519, 1994) orintramuscularly (Wang et al., Proc. Natl. Acad. Sci. USA 90: 4156,1993); saline has been found to be a suitable diluent for DNA-basedantigens. Ten days to three weeks days later, the immunized animals areboosted with additional immunogen and periodically boosted thereafter ona weekly, biweekly or every third week immunization schedule.

Serum samples are periodically taken by retro-orbital bleeding ortail-tip excision for testing by dot-blot assay (antibody sandwich),ELISA (enzyme-linked immunosorbent assay), immunoprecipitation, or othersuitable assays, including FACS analysis. Following detection of anappropriate antibody titer, positive animals are given an intravenousinjection of antigen in saline. Three to four days later, the animalsare sacrificed, splenocytes harvested, and fused to a murine myelomacell line (e.g., NS1 or preferably Ag 8.653 [ATCC CRL 1580]). Hybridomacell lines generated by this procedure are plated in multiple microtiterplates in a selective medium (for example, one containing hypoxanthine,aminopterin, and thymidine, or HAT) to inhibit proliferation ofnon-fused cells, myeloma-myeloma hybrids, and splenocyte-splenocytehybrids.

Hybridoma clones thus generated can be screened by ELISA for reactivitywith RANK, for example, by adaptations of the techniques disclosed byEngvall et al., Immunochem. 8: 871 (1971) and in U.S. Pat. No.4,703,004. A preferred screening technique is the antibody capturetechnique described by Beckman et al., J. Immunol. 144: 4212 (1990).Positive clones are then injected into the peritoneal cavities ofsyngeneic rodents to produce ascites containing high concentrations (>1mg/ml) of anti-RANK monoclonal antibody. The resulting monoclonalantibody can be purified by ammonium sulfate precipitation followed bygel exclusion chromatography. Alternatively, affinity chromatographybased upon binding of antibody to protein A or protein G can also beused, as can affinity chromatography based upon binding to RANK protein.

Monoclonal antibodies were generated using RANK/Fc fusion protein as theimmunogen. These reagents were screened to confirm reactivity againstthe RANK protein. Using the methods described herein to monitor theactivity of the mAbs, both blocking (i.e., antibodies that bind RANK andinhibit binding of a ligand to RANK) and non-blocking (i.e., antibodiesthat bind RANK and do not inhibit ligand binding) were isolated.

EXAMPLE 8

In this assay, test molecules capable of modulating an activityassociated with RANK are identified by measuring the induction of c-srctyrosine kinase or F-actin ring formation in the presence of the testmolecule.

Experiments were conducted in which DNA encoding wild-type or humanRANK/TRAF6 binding mutant (RANK α340-421) was introduced intohematopoietic cells isolated from RANK−/−mice. Full-length and mutanthuman RANK DNAs were subcloned into the pBMNZ retroviral vector aspreviously described (Kinsella and Nolan, 1996, Human Gene Therapy7:1405-1413). Infectious RANK-containing retrovirus was produced in293-E Phoenix packaging cells as described (Kinsella and Nolan, 1996).Supernatants from these cells were used as a source of infectious virusparticles.

The generation of the RANK−/−mice used in these assays has beendescribed previously (Dougall et al., 1999). Spleen cells were isolatedfrom 3-6 week old RANK−/−mice and enriched for osteoclast precursors bydepleting the initial cell population of various types of cells otherthan osteoclast precursors. For this “depletion” step, the cells wereincubated with biotinylated antibodies against CD3 (specific for Tcells), Ter-119 (specific for erythrocytes), and GR-1 (specific forgranulocytes). After the antibodies had bound to their respective targetcells, streptavidin-conjugated magnetic beads were added to the culture,and the mixture of cells was passed over magnetic columns (MACSdepletion columns; MILLTENNYI). Cells that did not adhere to the MACScolumns were considered to be enriched for osteoclast precursors andwere used for the assays.

Cells enriched for osteoclast precursors were incubated for 48 hrs in 40ng/ml CSF-1 prior to being infected with retroviral supernatants (MOI of5) in the presence of recombinant fibronectin fragments (Retronectin,PanVera Corp, Madison, Wis.) for an additional 48 hr in 40 ng/ml CSF-1.Both the cells and the virus particles tend to adhere to fibronectin,thus the fibronectin fragments served to enhance the rate of infectionby creating a localized high concentration of both cells and virus.Following infection, the cells were harvested and plated in a-MEM 10%fetal bovine serum containing 40 ng/ml CSF-1 and 200 ng/ml MRANK-L andwere incubated for 5 days in this medium.

For infected cultures that received wild-type RANK DNA, c-src levelswere fairly high following differentiation. In a typical experiment,extracts from cells expressing wild-type RANK wall incorporate about15-fold more ³²p into a c-src-specific substrate than extracts fromcells that are defective in RANK. Both fetal bovine serum and CSF-1contribute to the basal level of c-src activity, thus this basal levelwas reduced by “starving” the cells for 18 hrs in MEM containing 0.5%instead of 10% fetal bovine serum and 10 ng/ml instead of 40 ng/mlCSF-1, followed by 2 hours in MEM containing 0.5% FBS and no CSF-1.

To induce c-src and F-actin rings, recombinant mRANK-L/leucine zipperprotein was added to the cultures at a concentration of 1 μg/ml forvarious times after which the cells were lysed in a buffer containing 50mM HEPES (pH 7.2), 10% glycerol, 250 mM NaCl and 1% Triton X-100. Thec-src protein was purified by immunoprecipitation using the monoclonalantibody GD-1. C-src activity in the immune complex was monitored usinga commercially available assay kit (Upstate Biotechnology, Lake Placid,N.Y.). In brief, the measurement of c-src activity entailed measuringthe phosphotransferase activity using γ-labeled ATP and the p34/cdc2peptide (KVEKIGEGTYGVVYK) (SEQ ID NO:13), which provides a substrate forthe c-src kinase. The kinase assays were incubated at 30° C. for 10minutes in a buffer containing 10 μCi of gamma-labeled ATP, MnCl₂ (75mM), ATP (500 μM), MOPS (20 mM), beta-glycerol phosphate (25 mM), EGTA(5 mM), sodium orthovanadate (1 mM), and dithiothrietol (1 mM). Thephosphorylated substrate peptide was then separated from the residuallabeled ATP using phosphocellulose paper and labeled peptide wasquantified using a scintillation counter. The immunoprecipitation and invitro immune complex kinase assay were performed as described (Musch, etal. J. Biol. Chem. (1999) 274:7923-7928).

When c-src induction was assayed as described above, it was observedthat when cells were induced to differentiate after the introduction ofa full-length RANK transgene, the cells contained high levels of c-srcactivity. In contrast, c-src activity was not discernibly different frombackground levels in extracts of cells differentiated after infectionwith either a control virus (encoding lacZ) or with RANK DNA lacking theTRAF6 binding domain (RANK Δ340-421). Background levels were determinedusing RANK−/−cells that were not infected with retrovirus.

A procedure to detect F-actin rings was carried out as follows. Primaryhematopoietic cells from the RANK−/−mice were infected with retroviralconstructs encoding either the full-length human RANK cDNA or theRANK/TRAF6 binding mutant (RANK Δ340-421). Cells were cultured on LabTekChamber slides with #1 borosilicate coverglasses (Nalge/Nunc). Afterincubation for 5 days in MEM containing 10% fetal bovine serumcontaining 40 ng/ml CSF-1 and 200 ng/ml mRANK-L. The media wasaspirated, washed twice in PBS and then fixed in a solution of 3%paraformaldehyde for 10 minutes, followed by quenching in 50 mM NH₄Cl.The F-actin rings were visualized by staining the cells with afluorescent probe for actin, phalloidin (Molecular Probes, Eugene,Oreg.). The fluorescent signal was detected using a standard fluorescentmicroscope, and F-actin rings were identified as continuous rings ofF-actin at the periphery of individual cells.

F-actin rings were visualized in the cells by staining with fluorescentphalloidin. For cells infected with wild-type RANK DNA, F-actin ringswere detected in more than 50% of the cells. However, when the cells hadbeen transfected with the human RANK/TRAF6 binding mutant, all of thecells had a disorganized F-actin cytoskeletal structure and no F-actinrings were discerned.

To assay for an agonist of RANK activity, a test molecule is added tothe culture medium during the RANK-L exposure step, or after thedifferentiation step is completed. If the test molecule is an agonist ofRANK activity, cells infected with the above-described deletion mutantwill express F-actin rings or will express detectable c-src activity orboth. However, RANK agonists that require the presence of a TRAF6binding site in the RANK molecule will not test positive in RANK−/−cellsinfected with a RANK TRAF6 deletion mutant.

EXAMPLE 9

The resorption of CaPO₄, upon which this assay is based, is consideredto be a measure of osteoclast activity. Spleen cells were isolated from3-6 week old RANK−/−mice and treated as described in Example 9 to removecells expressing the CD3, Ter-119, and GR-1 antigens. Cells notexpressing any of these antigens were harvested and infected asdescribed in Example 9 with retroviral vector particles containingfull-length or TRAF6 binding site deletion mutants of RANK.

Following infection, the spleen cells were harvested and plated in MEMcontaining 10% fetal bovine serum containing 40 ng/ml CSF-1 and 200ng/ml mRANK-L onto 16 well quartz slides coated with a thin film ofCaPO₄ (Osteologic, BD Biosystems). After 5 days in culture, the slideswere washed, the cells removed by washing with bleach, and the slideswashed again with buffer. Cells that had been infected with full-lengthRANK resorbed the CaPO₄ matrix as determined by numerous clear pits(also called resorptive lacunae), which were visualized byphase-contrast microscopy. The number of pits in the CaPO₄ film is ameasure of the extent to which the RANK-L induced the cells grown onthat slide to differentiate into osteoclasts.

If desired, the CaPO₄ film can be stained using a 0.5% solution ofalizarin red for 4 to 5 minutes followed by washing in water. Afterstaining, the resorptive lacunae are visualized by phase contrastmicroscopy as a clear area on a red background.

Cells that have been differentiated using the full-length RANK transgenecontained high levels of CaPO₄ resorption. While cells differentiatedwith either a control virus (encoding lacZ) or with the RANK constructlacking the TRAF6 binding domain (RANK D340-421) had insignificantlevels of CaPO₄ resorption.

While the preferred embodiment of the invention has been illustrated anddescribed, it will be appreciated that various changes can be madetherein without departing from the spirit and scope of the invention.

1. A method for screening for a molecule that agonizes or antagonizesRANK activity in cells expressing RANK, wherein RANK is a polypeptidethat is capable of activating NF-κB and that is selected from the groupconsisting of: i) amino acids 1-616 of SEQ ID NO:2; ii) amino acids1-625 of SEQ ID NO:4; and iii) a polypeptide having an at least 90%amino acid sequence identity with (i) or (ii), said method comprisingthe steps of: (a) contacting a candidate molecule with cells expressingRANK, said RANK expressing cells comprising a nucleic acid moleculeencoding a reporter protein, said nucleic acid molecule being operablylinked to a RANK-responsive regulatory nucleic acid sequence that isselected from the group consisting of a human or murine MMP-9 promoterand a human or murine TRAP promoter, wherein the cells are exposed to aRANK trigger prior to, during or after being contacted with saidcandidate molecule; (b) determining whether the level of reportermolecule expression in the contacted cells is enhanced or reduced ascompared with the level of reporter molecule expression in a culture ofreference RANK expressing cells that are not contacted with thecandidate molecule; and (c) identifying the candidate molecule as a RANKagonist if the level of reporter molecule expression in the contactedcells is comparatively enhanced and identifying the candidate moleculeas an RANK antagonist if the level of reporter molecule expression inthe contacted cells is comparatively reduced.
 2. The method of claim 1,wherein RANK is triggered in the RANK expressing cells by a methodselected from the group consisting of: (a) contacting the cells with aRANK-L polypeptide, wherein the RANK-L polypeptide comprises amino acids162-317 of SEQ ID NO:6; (b) contacting the cells with an agonisticanti-RANK antibody; (c) contacting the cells with cells that expressRANK-L, wherein RANK-L is a polypeptide that comprises amino acids162-317 of SEQ ID NO:6; and (d) overexpressing RANK in said RANKexpressing cells.
 3. The method of claim 2, wherein RANK is triggered inthe RANK expressing cells by contacting the cells with a RANK-Lpolypeptide comprising amino acids 162-317 of SEQ ID NO:6 , and furtherwherein said RANK-L polypeptide is selected from the group consisting ofnative RANK-L, a leucine zipper fusion of RANK-L, and a FLAG polyHisfusion of RANK-L.
 4. The method of claim 1, wherein the RANK responsiveregulatory nucleic acid is a MMP-9 promoter.
 5. The method of claim 4,wherein the MMP-9 promoter comprises nucleotides 1769-3591 of SEQ IDNO:11.
 6. The method of claim 1 wherein the step of contacting RANKexpressing cells with a candidate molecule comprises expressing in saidcells an introduced DNA molecule that encodes a candidate nucleic acidmolecule or a candidate protein molecule.
 7. The method of claim 6wherein said introduced DNA molecule is a cDNA molecule.
 8. The methodof claim 6 wherein said introduced DNA molecule is integrated into thegenome of said cells.
 9. The method of claim 6 wherein said introducedDNA molecule is not integrated into the genome of said cells.
 10. Themethod of claim 6 wherein said candidate molecule is a protein encodedby the introduced DNA molecule.
 11. The method of claim 6 wherein saidcandidate molecule is a nucleic acid molecule encoded by the introducedDNA molecule.
 12. The method of claim 11 wherein said nucleic acidmolecule possesses ribozyme activity.
 13. The method of claim 6, furthercomprising isolating said introduced DNA molecule from a colony formedfrom said contacted cells.
 14. The method of claim 1, wherein the stepof contacting RANK expressing cells with a candidate molecule comprisesculturing said cells in the presence of the candidate molecule, andfurther wherein said candidate molecule is a protein.
 15. The method ofclaim 1, wherein the step of contacting RANK expressing cells with acandidate molecule comprises culturing said cells in the presence ofsaid candidate molecule.
 16. The method of claim 1, wherein saidreporter molecule is selected from the group consisting of luciferase,green fluorescent protein, alkaline phosphatase and a heterologoussurface protein.
 17. The method of claim 16, wherein the reportermolecule is a heterologous surface protein that is selected from thegroup consisting of human IL-2 receptor, murine IL-4 receptor, human CD2protein, human CD4 protein, human CD8 protein, luciferase protein,β-galactosidase, and green fluorescent protein.
 18. The method of claim1, wherein said RANK expressing cells express a defective RANK moleculeand wherein said screening is for an agonist that complements saiddefective RANK activity.
 19. The method of claim 1, wherein said RANKexpressing cells are hematopoietic cells.
 20. The method of claim 1,wherein said RANK expressing cells are RAW 264.7 cells.
 21. The methodof claim 1, further comprising the step of purifying the candidatemolecule from cells in which the level of expressed reporter molecule isdetermined to be comparatively enhanced or reduced.
 22. The method ofclaim 1, wherein the level of reporter molecule expression is determinedby an assay selected from the group consisting of a fluorescence-basedassay, a solid phase assay, and an assay employing a radioactivecompound.
 23. The method of claim 1, wherein determining the level ofexpressed reporter molecule comprises physically isolating byfluorescence-based cell sorting the cells that are expressing saidreporter molecule.
 24. A method according to claim 1, wherein the MMP-9promoter is a murine promoter comprising nucleotides 1769-3591 of SEQ IDNO:11 and the TRAP promoter is a murine promoter comprising nucleotides1-1991 of SEQ ID NO:12.
 25. A method for screening for a molecule thatagonizes or antagonizes RANK activity, said method comprising the stepsof: (a) contacting a candidate molecule with cells expressing adefective RANK polypeptide consisting of amino acids 1-622 of SEQ IDNO:10, said cells comprising a nucleic acid molecule encoding a reporterprotein, said nucleic acid molecule being operably linked to aRANK-responsive regulatory nucleic acid sequence that is selected fromthe group consisting of a human or murine MMP-9 promoter and a human ormurine TRAP promoter; (b) determining whether the level of reportermolecule expression in the contacted cells is enhanced or reduced ascompared with the level of reporter molecule expression in a culture ofreference cells expressing said defective RANK and comprising saidnucleic acid molecule that are not contacted with the candidatemolecule; and (c) identifying the candidate molecule as a RANK agonistif the level of reporter molecule expression in the contacted cells iscomparatively enhanced and identifying the candidate molecule as a RANKantagonist if the level of reporter molecule expression in the contactedcells is comparatively reduced.